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ABSTRACT OF DISSERTATION  
   
 
INVESTIGATING KEY POST-PKS ENZYMES FROM GILVOCARCIN 
BIOSYNTHETIC PATHWAY  
  
    
          
       Gilvocarcin V (GV) belongs to the angucycline class of antibiotics that 
possesses remarkable anticancer and antibacterial activities with low toxicity. Gilvocarcin 
exhibits its light induced anticancer activity by mediating crosslinking between DNA and 
histone H3.  When photo-activated by near-UV light, the C8 vinyl group forms a [2+2] 
cycloadduct with thymine residues of double stranded DNA. D-fucofuranose is 
considered essential for histone H3 interactions. However, the poor water solubility has 
rendered it difficult to develop gilvocarcin as a drug. We aim to design novel gilvocarcin 
analogues with improved pharmaceutical properties through chemo-enzymatic synthesis 
and mutasynthesis. Previous studies have characterized many biosynthetic genes 
encoding the gilvocarcin biosynthetic skeleton. Despite these previous findings the exact 
functions of many other key genes are yet to be fully understood. Prior gene inactivation 
and cross-feeding experiments have revealed that the first isolable tetracyclic aromatic 
product undergoes a series of steps involving C–C bond cleavage followed by two O-
methylations, a penultimate C-glycosylation and final lactone formation in order to fully 
develop the gilvocarcin structure.  
To provide a deeper understanding of these complex biochemical transformations, 
three specific aims were devised: 1) synthesis of the proposed intermediate and in vitro 
enzyme reactions revealed GilMT and GilM’s roles in gilvocaric biosynthesis; 2) 
utilizing in vitro studies the enzyme responsible for the C–C bond cleavage and its 
substrate were determined; 3) a small series of structural analogues of the intermediate 
from the gilvocarcin pathway was generated via chemical synthesis and fed to the 
 
mixture of the enzymes, GilMT and GilM. These reaction mixtures were then analyzed to 
establish the diversity of substrates tolerated by the enzymes.  
Keywords: Gilvocarcin, S-adenosylmethionine, O-methyltransferase, Baeyer-Villiger 
monooxygenases. 
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Chapter 1. Introduction 
Survival, instinct, and competitiveness are the key that frames these diverse 
chemical entities known as natural products within the organisms. Natural products have 
been the source of the majority of FDA-approved agents and continue to inspire 
researchers in the field of drug discovery. The serendipitous discovery of pencillin by 
Alexender Fleming in 1928 and its development for use as a medicine in 1941 by 
Howard Walter Florey, together with Ernst Chain constitute a major breakthrough in 
medical history.  
 
Figure 0.1 Natural Products 
2 
 
We broadly classify NPs into six categories based on their building blocks and 
biosynthetic routes: alkaloids (1 and 2), fatty acids and polyketides (3), terpenoids and 
steroids (4 and 5), nonribosomal peptides (6), and specialized carbohydrates (7) (Figure 
1.1).(1) 
1.1. Polyketides 
Polyketides are complex small molecules that come from a variety of biological 
sources, mostly from microbes. Microorganisms, plants and insects make a wealth of 
these natural products to serve as pigments, virulence factors, or as defence weapons. 
Polyketides represent one of the major classes of natural products that exhibit a 
remarkable range of structural and functional diversity. Polyketides are known to possess 
a vast array of pharmaceutical functions such as antibiotic, immunosuppressant, 
antiparasitic, cholesterol-lowering, and antitumor properties.  Others are infamous toxins 
or virulence factors.(2) Commercially important polyketides include antibiotics 
(oxytetracycline, erythromycin, monensin),  anticancer agents (doxorubicin, 
mithramycin), immunosuppressants (FK506), antifungals (amphotericin B), and 
cholesterol-lowering (lovastatin) agents (Figure 1.2).(1)  
Because of the high pharmaceutical significance of polyketides there have been 
constant efforts to synthesize their complex scaffolds. Synthetic chemistry has long been 
used to generate structural analogues of natural product drug candidates with improved 
pharmacological properties. Although total synthesis of natural products offers a 
promising opportunity to provide pharmacologically improved molecules frequently it 
becomes challenging to scale due to the structural complexity of these molecules. An 
alternative to this approach is mutasynthesis (or chemo-enzymatic synthesis), which 
utilizes synthetic chemistry to construct analogues of the intermediates in the pathway, 
leaving the remaining, more difficult, alterations to be accomplished by the enzymrs of 
the producing organism.(3, 4) To be able to construct the bioactive polyketides, a deeper 
knowledge of their biosynthesis is vital. Better understanding can allow us to become 
better polyketide engineers enabling us to create new and improved drug therapies.  
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Figure 0.2 Polyketide drugs. 
1.2. Polyketide biosynthesis  
The most intriguing aspect of structurally complex polyketides is that they are 
derived from mostly simple building blocks in nature including, acetate and 
propionate.(5) Polyketide biosyntheses are catalyzed by complexes of mono or multi-
functional enzymes called polyketide synthases (PKSs). The chemistry associated with 
PKSs is closely related to that of the well-studied fatty acid synthases (FASs). Polyketide 
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biosynthesis overlaps with fatty acid synthesis not only in terms of mechanistic details 
involved in chain elongation process but also in that both the utilize common precursors 
such as acetyl coenzyme A (CoA), malonyl CoA.(6) In general, fatty acids and 
polyketides are biosynthesized through the repititive decarboxylative condensations of 
activated acyl starter unit with malonyl-CoA derived extender units to generate poly β-
ketoester intermediates (Scheme 1.1).  
 
Scheme 0.1 The fatty acid and polyketide biosynthetic cycles. MAT: malonyl-acetyl transferase; 
ACP: acyl carrier protein; KS: ketosynthase; KR: ketoreductase; DH: dehydratase; ER: enoyl 
reductase. 
FAS is a large multienzyme complex. The biosynthesis of fatty acids takes place 
two carbons at a time (Scheme 1.1), where the starter unit, derived from acetyl-CoA, is 
anchored to a ketosynthase (KS) and the extender unit, derived from manolyl-CoA, is 
tethered to an activated acyl carrier protein (holo-ACP). Release of carbon dioxide from 
malonic acid renders it nucleophilic enough to attack the KS bound acetyl-CoA resulting 
in the production of an ACP bound β-keto-acyl-thioester thus elongating the chain by two 
carbon atoms. The β-carbonyl generated during FA synthesis is reduced to an alcohol by 
a ketoreductase (KR), this resulting β-hydroxy is then dehydrated by a dehydrogenase 
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(DH) to give an alkene. Finally, the alkene will be hydrogenated by an enoylreductase 
(ER) to give a fully saturated fatty acyl ACP. This process of condensation, 
ketoreduction, dehydration and hydrogenation converts highly oxidized starter molecules 
to a fully saturated acyl backbone which can then return to the KS as two carbon 
extended chain and can go through this cycle again and again until a full length chain is 
obtained. The terminal step in the pathaway is the release of the full-length fatty acid by 
the enzyme ketoesterase (KE). In comparison to fatty acids, polyketides are more 
complex. Unlike FASs that only uses malonyl-CoA, PKSs can use a variety of building 
blocks, can terminate the chain elongation steps at any point in the reduction cycle, and 
can add modifications at any stage generating much higher level of functionality in a 
polyketide. 
On the basis of their biosynthetic machinery, polyketides are usually categorized 
as type I-, type II- and type III-PKS derived.(7) Type I PKSs consist of large 
multifunctional enzyme complexes that can be further classified as either modular (for 
example, macrolides like erythromycin) or iterative (for example, the lovastatin 
nonaketide synthase).(8) Each of these type I modular proteins consists of multiple active 
domains organized into modules where each module consists of a minimal PKS 
(composed of KS, AT and ACP) along with optional β-keto processing domains (KR, 
DH, ER).  Each catalytic and carrier domain is used only once as the growing chain is 
passed along the assembly line and is responsible for a single carbon–carbon bond 
formation followed by programmed reduction/ dehydration cycles. Thus, the number of 
modules determines the number of cycles catalyzed by a particular type I PKS and 
corresponds to the number of newly formed C–C bonds. The presence of KR, DH and ER 
domains depicts the degree of reduction that the β-keto group undergoes in each module. 
Overall, the number and organization of catalytic domains in each module largely reflects 
upon the chemical structure of the polyketide. The PKS involved in 6-deoxyerythronolide 
B (16) biosynthesis represents the textbook-example of a modular polyketide synthase 
(Scheme 1.2). 
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Scheme 0.2 6-deoxyerythronolide B (16) biosynthesis. 
The cluster is composed of three very large proteins namely DEBS1, DEBS2 and 
DEBS3 producing a total of six modules in addition to a loading module and a 
termination enzyme.(9-11) The biosynthesis commences with the loading of a starter unit 
of propionyl-CoA to the holo-ACP domain; this is then passed onto the first module that 
also picks up a methylmalonyl-CoA. Decarboxylative claisen-condensation between the 
starter unit and the extender unit results in the formation of ACP-tethered diketide. The 
KR domain then reduces the β-carbonyl and results in the formation of a hydroxyl group 
at the C3 position. The AT domain catalyzes the transfer of the growing chain to the next 
module, module 2, that adds two more carbons and passes the chain to module 3. The 
third module lacks any reductive domain leaving the β-carbonyl intact after the addition 
of two carbons and passes the growing chain to the next module, module 4. The process 
continues through the remainder of the modules where the chain elongates until the 
designated chain length is achieved. In the final step the fully-grown chain reaches the 
terminal domain that has thioesterase (TE) activity. The TE catalyzes an intramolecular 
lactone formation while simultaneously releasing the fully-grown PKS product. The 
nucleophilic hydroxyl group at C13 position attacks the carbonyl carbon of the thioester 
facilitating the formation of 6-erythronolide B (16).  
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Apart from typical bacterial modular type I PKSs, there are other type I PKSs 
found in fungi characterized by an iteratively acting multidomain enzyme. These iterative 
type PKSs are mysterious in that it still remains unclear how a single multifunctional 
enzyme makes choices about the degree of reduction at each chain extending 
condensation. The iterative type I PKSs are typically found in the biosynthesis of fungal 
polyketides such as 6-methylsalicylic acid, lovastatin and aflatoxin. Lovastatin 
biosynthesis involves two type I PKSs, one being a noniterative PKS responsible for the 
formation of 2-methylbutyrate side chain and the other an iterative type I PKS (LovB) 
that specifies the formation of the main nonaketide-derived skeleton.(12) The KR, DH, 
and ER domains are optionally used in every round of chain elongation (Scheme 1.3).  
 
Scheme 0.3 Lovastatin biosynthesis. 
Aromatic polyketides such as actinorhodin (18), landomycin A (17), kinamycin F 
(20), gilvocarcin V (19), and jadomycin A (21); are assembled by iteratively operating 
type II PKSs (Figure 1.3).  Unlike type I PKSs, these multienzyme complexes iteratively 
use a ketosynthase heterodimer (KSα and KSβ) that catalyzes condensation of a growing 
poly-β-keto ester chain with malonyl-CoA units. Ketoacyl synthases [KSα and KSβ, also 
called chain length factor, CLF] and the ACP together constitute the minimal PKS 
(Scheme 1.4).(13) The major hallmark difference between type I and type II PKSs is that 
the latter does not include β-keto reduction cycles. Thus, at the end of chain enlongation 
the type I minimal PKS produces a highly reactive poly β-keto ester intermediate. Apart 
from the minimal PKS enzyme complex other tailoring enzymes such as ketoreductases 
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(KRs), cyclases (CYCs), and aromatases (AROs) are required to determine the folding, 
cyclization, and aromatization pattern of the polyketide chain. Type II PKSs are found in 
prokaryotes (5) and, with the exception of a few other Gram-negative bacteria, are found 
exclusively in the soil borne bacteria actinomycetes. (14, 15) The complete gene cluster 
for the biosynthesis of actinorhodin (18) was first cloned in 1984 followed by complete 
Streptomyces coelicolor genome sequencing in 1992.(16, 17) The starter unit 
incorporated in the biosynthesis is either acetyl-CoA or propionyl-CoA, and seven 
molecules of malonyl-CoA are used as the extender units. (Scheme 1.4).(16).  
 
Figure 0.3 Some examples of type II PKS derived antibiotics. 
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Scheme 0.4 Polyketide chain formation/elongation by type II PKSs. 
The type III iterative PKSs are relatively small dimeric proteins that do not 
require an ACP with its phosphopantetheinyl arm on which the growing polyketide 
chains are tethered, and instead utilize acyl-CoA substrates directly.(5) Type III PKSs are 
most commonly found in plants. These enzymes are responsible for the synthesis of 
compounds such as stilbenes and chalcones and are more commonly known as 
stilbene/chalcone synthases (SHS or CHS). The first bacterial type III PKS, RppA, was 
reportedly from Streptomyces griseus, and catalyzes the synthesis of 1,3,6,8-
tetrahydroxynaphthalene (THN). RppA utilizes five molecules of malonyl-CoA, which 
undergo spontaneous oxidation to form flaviolin (22) (Scheme 1.5).(18)  
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Scheme 0.5 Type III PKS-mediated biosynthesis of Flaviolin (22). 
In addition to the three broadly classified types of polyketide sythases there are 
other mixed type polyketide synthases, such as type I-type II, type I-type III, FAS-PKS 
hybrid and PKS-NRPS-hybrides (NRPS stands for non-ribosomal peptide synthase) as 
exemplified by lankacidin C, kendomycin, DIF-1, jamaicamide A, respectively.(5, 19)  
1.3. Post-PKS tailoring enzymes 
The fully condensed products of PKS catalyzed reactions usually undergo a series 
of tailoring events (also known as post-PKS events) such as glycosylation, methylation, 
oxidation, reduction, prenylation, and halogenation to generate biologically active 
structurally diverse compounds (Figure 1.4). Such tailorings can tremendously alter the 
pharmacological properties of the parent polyketides, impacting facors such as solubility 
or receptor binding ability of the modified parent compound. These post-PKS events 
usually result in the conversion of a biologically non-active polyketide into an active 
product. The conversion of inactive 6-deoxyerythronolide B (16), to potent antibacterial 
agent, Erythromycin A (12) well illustrates the effect of such tailoring events.(20) These 
post-PKS tailoring reactions provide a unique handle to decorate the initial natural 
product frame by means of combinatorial biosynthesis or precursor-directed biosynthesis. 
Tailoring enzymes such as oxidoreductases, group transferases, halogenases, cyclases, 
and deoxysugar biosynthetic enzymes have been extensively used to generate modified 
polyketides, occassionally with improved pharmacological properties.(21) Some 
commonly occuring post-PKS tailoring reactions are briefly discussed in the following 
section. 
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Figure 0.4 Post-PKS tailoring steps.Adapted from Olano et al.(21) 
Oxygenases 
The products of PKSs often go through multiple oxidative steps that introduce 
structural diversity to these molecules. The oxygenases modify the framework through 
the introduction of oxygen-containing functionalities, such as hydroxy, epoxide, aldehyde 
and keto groups, and through oxidative C–C bond cleavages, oxidative ring closing. Such 
oxidative events provide handles for other post-PKS modifications such as O-methylation 
and O-glycosylation. Common oxygenases known to play a role in natural product 
biosyntheses are cytochrome P-450 monooxygenases (CYP450s), flavin-dependent 
monooxygenases, dioxygenases, and co-factor free anthrone oxygenases. (22, 23) 
Oxygenases directly catalyze the addition of oxygen from molecular oxygen to the 
substrate. Depending on the number of oxygen atoms introduced into the substrate, they 
can be further classified as monooxygenases (uses one O-atom from an O2-molecule) 
(Scheme 1.6) and dioxygenases (adds both O-atoms of an O2-molecule). Most of the 
monooxygenases utilize NADH, NADPH or ascorbic acid as reducing equivalents to 
reduce the second oxygen molecule to water. The most studied examples of these 
monooxygenases are cyctochrome P-450 monooxygenases (CYP450s).(23) 
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Scheme 0.6 Monooxygenases. 
CPY450s belong to a very large and diverse family of proteins containing heme 
as a cofactor and, hence, are hemeproteins. CYP450s play a critical role in the primary 
and secondary metabolic pathways as well as in drug detoxification pathways. Most 
CYPs pair up with a multi-component electron transfer system that constitutes of a 
protein partner to supply one or more electrons for iron reduction. However, some CYPs 
can be one-component, i.e., they do not require any external reducing partner. In the 
presence of molecular oxygen, the cofactor NAD(P)H, and an electron transfer system 
the CYPs catalyze a diverse array of regio and sterospecific reactions including the 
epoxidation of C–C double bonds and aliphatic/ aromatic hydroxylations. CYP450 
catalyzed reactions are commonly observed in post-PKS modifications. The 
understanding of CYP450 function is essential for the efficient engineering of 
Streptomyces strains capable of generating novel antibiotics.  For example, the improved 
biosynthesis of pladienolide D from recombinant Streptomyces platensis will be 
discussed. Streptomyces platensis produces pladienolide B (23) and only minor amounts 
of its 16-hydroxylated derivative pladienolide D (24) that posseses strong anti-cancer 
activity. The pladienolide B 16-hydroxylase PsmA from Streptomyces bungoensis A-
1544 was overexpressed in a recombinant Streptomyces platensis strain enhancing the 
production of pladienolide D (24) to a level comparable to that of pladienolide B 
(23).(24) Approaches that utilize substrate promiscuity of CYP450s have also been 
applied to generate novel analogues of erythromycin and pikromycin.(25-27) 
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Scheme 0.7 Biosynthesis of the polyketide macrolide pladienolide D (24) in recombinant 
Streptomyces platensis: CYP450 mediated hydroxylations and epoxidation. 
Another class of monooxygenases that have gained researchers’ attention is that 
of the Baeyer-Villiger monooxygenase (BVMO). The flavin-dependent Baeyer-Villiger 
monooxygenases involved in secondary metabolite biosynthetic pathways catalyze C–C 
bond cleavage through the insertion of an oxygen atom in cyclic ketone to form a lactone. 
Examples of this activity are seen in the BVMOs MtmOIV in the mithramycin 
biosynthetic pathway and CmmOIV in the chromomycin biosynthetic pathway.(28, 29) 
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MTM biosynthesis proceeds through the polyketide derived tetracyclic 
premithramycinone, which undergoes glycosylation and methylation at the 9-position to 
give premithramycin B (25). A Baeyer-Villiger reaction catalyzed by MtmOIV then 
oxidatively cleaves the C-C bond in the the fourth ring generating the tricyclic aglycone 
core and highly functionalized pentyl side chain at the 3-position, mithramycin DK, the 
penultimate intermediate of the mithramycin biosynthetic pathway (Scheme 1.8).(28, 30) 
Mechanistically, two electrons and two protons are transferred from NADPH to FAD 
generating FADH2 transiently. The reduced flavin immediately reacts with an 
atmospheric oxygen molecule to generate a reactive peroxyflavin. Nucleophilic attack of 
the peroxyflavin on the ketone carbon generates a tetrahedral intermediate also know as a 
Criegee intermediate. A subsequent concerted step involves the migration of one of the 
adjacent carbons to the oxygen thereby generating a lactone (Scheme 1.9).   
Apart from cofactor-dependent monooxygenases, there are some 
monooxygenases that do not require any cofactor and/or a transition metal ion to activate 
molecular oxygen. Quinone forming monooxygenases compose a unique group of 
cofactor-free monooxygenases that catalyzes the oxidation of naphthacenone- and 
anthrone- type precursors of type II polyketides to form the corresponding quinone 
derivatives. For example, tetracenomycin F1 monooxygenase (TcmH) from the 
biosynthetic pathway of the antitumor antibiotic tetracenomycin C. (33) TcmH catalyzes 
the oxidation of the naphthacenone tetracenomycin F1 at position C-5 to the 5,12-
naphthacenequinone tetracenomycin D3 (29) (Scheme 1.10). TcmH does not require any 
cofactor for catalysis and uses its substrate as the reducing equivalent for the reduction of 
one oxygen atom of molecular oxygen to water.(31) Other cofactor free anthrone 
oxygenases include ActVA-orf6 from Streptomyces coelicolor A3 (32) and ElmH from 
Streptomyces olivaceus.(33)  
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Scheme 0.8 MtmOIV-catalyzed Baeyer-Villiger oxidation of premithramycin B. 
 
Scheme 0.9 Mechanism of BVMO catalysis. 
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Dioxygenases 
As the name suggests, a dioxygenase incorporates both oxygen atoms of dioxygen into a 
substrate resulting in a dioxetane or a peroxide. These often a highly reactive species can 
rearrange or react further, e.g. into a 1,2-diol. Tetracenomycin A2’s oxygenase TcmG 
from tetracenomycin C’s (33) biosynthetic pathway catalyzes a triple hydroxylation in 
the final step to yield tetracenomycin C via a monooxygenase-dioxygenase mechanism 
(Scheme 1.10).(34) 
 
Scheme 0.10 Post-PKS tailoring steps in the biosynthetic pathway of the antibiotic 
tetracenomycin C (33). 
Glycosylation 
Glycosylation in natural product biosynthesis not only imparts structural diversity 
but also is important for the biological activity of these compounds. These sugars usually 
play a critical part in the molecular recognition of  a molecules cellular target.(35) The 
classic textbook example includes activation of the inactive aglycon 6-DEB after 
glycosylation, which introduces two sugar moieties converting it into erythromycin, a 
potent antibiotic.(11) These sugars can be linked to the acceptor substrate as 
monosaccharides, disaccharides or oligosaccharides through O-, C-, S- or N-glycosidic 
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bonds. O-glycosides are by far the most widespread of the group in comparison to their 
realtively rare N-, S- and C-glycoside counter parts. Glycosylation typically occurs in the 
later stages of biosynthesis where the sugars are transferred to the corresponding acceptor 
substrate by an enzyme known as glycosyltransferases (GTs).  
Based on the stereochemical outcome, the GTs can be classified as either 
inverting or retaining (Scheme 1.11).(36) Inverting glycosyltransferases mediate 
nucleophilic attack of the acceptor substrate at the anomeric carbon of the activated 
sugar, with the simultaneous release of the leaving group in an SN2 fashion. This results 
in the inversion of the configuration of the anomeric carbon in the product with respect to 
the donor substrate. Koshland et al. first proposed the mechanism for the retaining GT in 
1953. The retaining glycosyltransferases mediate the formation of a glycosidic bond via a 
double displacement mechanism that involves a covalently bound glycosyl-enzyme 
intermediate species (Scheme 1.11, A). An alternative SN1 mechanism was also proposed 
where the activating group leaves first resulting in an enzyme-stabilized oxocarbenium 
ion intermediate species. This species is shielded on one face by the enzyme, thereby 
preventing back side attack of the incoming nucleophile and leading to complete 
retention of the anomeric configuration in the product (Scheme 1.11, B).(36)  
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Scheme 0.11 Proposed mechanism for inverting (A) and retaining (B) type O-
glycosyltransferases as well as C-glycoside formation (C). 
The C-glycosides from microbial secondary metabolites are also interesting as C-
glycosidic bonds unlike O-glycosidic bonds are quite stable. The sugar moiety is attached 
either at an ortho- or para-position with respect to an electron donating functional groups 
(e.g. hydroxyl) of the acceptor substrate’s aromatic moiety. Such electron rich groups 
increase the electron density at these positions, and hence make it possible to attack the 
anomeric center of the activated sugar as in the case of urdamycin A and gilvocarcin 
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V.(37, 38) The exact mechanisms for C- or N-glycosylations are still obscure, however a 
hypothetical mechanism has been proposed (Scheme 1.11, C).  
Methylation 
Another common PKS modification occurring in the biosynthesis of a variety of 
natural products is methylation, catalyzed by enzymes referred to as methyltransferases. 
Most of the methyltransferases use the reactive methyl group bound to sulfur in S-
adenosyl methionine (SAM) as the methyl donor. In a typical methylation reaction this 
methyl group is transferred to the acceptor substrate. The biosynthesis of the antitumor 
drug mithramycin by Streptomyces argillaceus presents an interesting example of both 
O- and C- methylations catalyzed by MtmMI and MtmMII respectively.(39)  
 
Scheme 0.12 Methyltransferase catalyzed reaction. 
Once again, the biosynthesis of tetracenomycin C (33) provides an excellent 
example, since it requires three methylation steps, which are catalyzed by three different 
SAM-dependent methyltransferases TcmN, TcmO and TcmP (Scheme 1.10).(40, 41) 
TcmN is an interesting bifunctional enzyme whose N-ternimal functions as a cyclase and 
its C-terminal contains 3-O-MT activity that converts tetracenomycin D3 (29) into 
tetracenomycin B3 (30). In the next step, the 8-O-methyltransferase, TcmO converts 
Tetracenomycin B3 into tetracenomycin E (31), which in turn is converted into 
tetracenomycin A2 (32) by the C-9 carboxymethyltransferase, TcmP. 
Another example is the biosynthesis of macrolide antibiotic, tylosin. While TylM 
and TylC3 catalyze an N-methylation and a C-methylation, respectively, during the 
biosynthesis on the NDP-sugars,(42, 43) TylE and TylF catalyze a double O-methylation 
in the final two steps of the tylosin biosynthesis.(44) Other well studied examples of O-
methylations are seen in the biosynthesis of daunorubicin,(45, 46) and erythromycin.(11)  
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Mutasynthesis 
 The above described biosynthetic enzymes incorporate small and simple 
precursors into the complex natural products by catalyzing the reactions in 
chemoselective and stereoselective manner. Many efforts to mimic this highly evolved 
biosynthetic machinery have been made to synthesize clinically relevant complex natural 
products and their analogues in abiotic chemical environment. Chemical synthesis of 
large and highly functionalized molecules is a difficult task. Another approach that has 
been successfully employed to generate such complex natural products is 
mutasynthesis.(3, 47) Mutasynthesis is a technique that couples the power of chemical 
synthesis with metabolic engineering. In mutasynthesis, synthetic chemistry is used to 
construct analogues of biosynthetic intermediates. The intermediates are then fed to the 
mutant strains (that lack enzymes for an early key step/multiple biosynthetic steps) of 
producing organism, thereby forcing the cellular uptake of surrogate substrates and their 
incorporation into the natural product derivatives.  
 
Scheme 0.13 Biosyntheses of ansamitocins. 
 One of the recent examples of mutasynthesis is the production of ansamitocin 
derivatives for structure-activity relationship study. The ansamitocins show high potency 
against the growth of different leukaemia cell lines as well as human solid tumors. 
Structurally similar ansamitocin and geldanamycin have related polyketide biosyntheses 
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with a common starter unit, aminohydroxybenzoic acid (AHBA, 34). Andreas Kirschning 
and his group selected two early stage mutant strains that are blocked in the formation of 
AHBA (Actinosynnema pretiosum HGF073 for ansamitocins and Streptomyces 
hygroscopicus var. geldanus K390-61-1 for geldanamycin). A third late stage A. 
pretiosum mutant was also used. This mutant blocked in the post-PKS modifications 
(chlorination and carbamoylation) mostly accumulated proansamitocin (35) along with 
small amounts of 10-epi-proansamitocin. Proansamitocin was then derivatized to 
generate the analogues. Feeding of the proansamitocin derivatives along with 
proansamitocin and epi-proansamitocin to the (–)-AHBA blocked mutant of S. 
hygroscopicus successfully produced new carbamoylated metabolites. With 
semisynthetic approach, a few carbanalogues were also produced. All the derivatives 
were tested for their antiproliferative activity in mouse fibroblast cells and human tumor 
cell lines. The structure-activity relationship study revealed that the stereochemistry at C-
9 is important for the activity, whereas the carbamate nitrogen is not crucial for the 
cytotoxicity (Figure 1.5). 
 
Figure 0.5 Antiproliferative activity of the selected ansamitocin derivatives synthesized 
via mutasynthesis-semisynthesis route. 
 Another example of mutasynthesis is diverization of the uridyl peptide antibiotic 
pacidamycin. The introduction of prnA, a gene encoding for halogenase activity from 
pyrrolnitrin biosynthesis, into Streptomyces coeruleorubidus resulted in the chlorinated 
pacidamycin. The installed chlorine provided a handle for funtionalization of the natural 
product via cross-coupling Suzuki reaction (Scheme 1.14). 
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Scheme 0.14 Gene expression enabling synthetic diversification of placidamycin. 
 
 Antibiotic Gilvocarcin V  
 
Figure 0.6 Representative members of the gilvocarcin group of natural products. 
Gilvocarcin V (GV, 19) also known as toromycin, is decorated with a C-
glycosidically linked sugar moiety. It is the most important representative of the 
benzo[d]naptho[1,2-b]pyran-6-one antibiotics possessing significant antitumor activity. 
(48, 49) Chrysomycin V (50), ravidomycin V (49) and polycarcin V (51) (Figure 1.6) 
represent other members of the family that contain the same aromatic core attached to 
various sugar moieties. Nakano et al. first isolated GV in 1981 from Streptomyces 
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gilvotanareus.(50-52). GV exhibits high potency against tumor cell lines while 
maintaining a low in vivo toxicity. Addition, GV serves as an antiviral and antibacterial 
agent.(49, 53, 54) Elespuru and Gonda identified light exposure of the gilvocarcins in the 
presence of DNA as a significant requirement for potency in cell culture.(55) In 1987, 
McGee and coworkers reported that gilvocarcin V intercalates into DNA in the dark and 
undergoes covalent adduct formation with DNA only in the presence of the light.(56) A 
detailed mechanistic study later revealed that when photo-activated GV mediates a [2+2] 
cycloaddition reaction of the C-8-vinyl side chain with DNA thymine residues and 
additionally causes cross-linking to histone H3.(57-60) For the latter, the C-
glycosidically-linked sugar moiety of the gilvocarcins appears to be crucial. GV photo 
activation at ~ 400 nm offers selective treatment of cancer, particularly lung cancer and 
colon cancer. Additionally, GV has the potential to treat brain cancer or cancer anywhere 
else that solid tumors can be reached through light capillaries.(61-63)  
In spite of being rich in various biological activities, predominantly anticancer 
and antibacterial, gilvocarcin V has not been developed into a clinically applied drug 
mainly due to low water solubility. Additionally, structural complexity of GV makes total 
synthetic approaches to the development of analogues very challenging and expensive. A 
deeper understanding of how the organism generates such scaffolds is necessary to 
develop GV analogues with improved activity through mutasynthesis and combinatorial 
biosynthesis.  
The GV producer, Streptomyces griseoflavus also produces two other minor 
congeners, gilvocarcin M (GM, 46) and gilvocarcin E (GE, 47). All three compounds 
(gilvocarcin V, M and E) have an identical tetracyclic aromatic moiety linked to D-
fucofuranose through C-4 glycosidic linkage, but GM and GE have a methyl group and 
ethyl group respectively at the C-8 position instead of the vinyl group of GV. 
Gilvocarcins M and E are far less photoactive compared to GV confirming the 
importance of the vinyl side chain for antitumor activity.(57)  
1.4. Biosynthetic Highlights of Gilvocarcin V  
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Initial feeding experiments with various 13C labeled acetate and propionate precursors 
showed that the unique gilvocarcin backbone originates from acetate and propionate via 
the polyketide route and the pathway involves a series of oxidative events along with a C-
C bond cleavage and O-methylations. (64-66) Gilvocarcins E and V incorporate 
propionate as starter unit resulting in a C-8 ethyl or vinyl side chain while gilvocarcin M 
incorporates acetate (Scheme 1.15).  
 
Scheme 0.15 Labeling pattern and hypothetical oxidative rearrangements. 
In 2003, Rohr et al. isolated the gilvocarcin gene cluster on a single cosmid, 
cosG9B3, from S. griseoflavus Gö3592.(67) The heterologous reconstitution of the GV 
pathway, accomplished by expressing cosG9B3 in S. lividans TK24, confirmed the 
presence of the complete gilvocarcin biosynthetic locus (gil). Sequencing and 
25 
 
bioinformatics analysis revealed the presence of the expected type II PKS genes 
(gilABCFKPQ) in black (Figure 1.7), four putative oxygenases (encoded by gilOI, OII, 
OIII, OIV) in red, a C-glycosyltransferase (encoded by gilGT) in green, a 
methyltransferase gene (gilMT) in blue, an oxidoraductase gene (gilR) in pink, 
deoxysugar biosynthetic genes (gilE, D and U) in green, and several other genes with 
unknown function such as gilNLVM along with putative repressor and resistance genes 
(Figure 1.7). 
 
Figure 0.7 GV biosynthetic gene cluster. 
After the isolation of the complete gene cluster initial studies involving the 
inactivation of the pathway oxygenases in cosG9B3 were conducted to determine the 
mode and sequence of the oxidative events involved in the generation of the gilvocarcin 
chromophore. The oxygenases were inactivated and the resulting mutant cosmids were 
heterologously expressed in S. lividans TK24. An observed accumulation of mostly 
gilvocarcin E (47) from ΔgilOIII mutant clearly disregarded gilOIII as being involved in 
C–C bond cleavage. However, absence of GV indirectly established the role of gilOIII in 
the formation of the vinyl side chain.(38) The culture broths of ΔgilOI or 
ΔgilOIΔgilOIIΔgilOIV mutants accumulated homo-prejadomycin (55-56) while homo-
rabelomycin (72) was identified as major metabolite from ∆GilOIV or GilOIV∆GilOII 
mutants(Scheme 1.13).(68, 69) Similarly dehydro-homo-rabelomycin (74) was isolated 
from a ∆GilOII mutant. None of the metabolites produced by single or sequential 
inactivations of gilOI, gilOII and/or gilOIV were the products of an oxidative 
rearrangement leading to the hypothesis that all three oxygenases were required for the 
C5–C6 bond cleavage. High sequence homologies between oxygenases from the similar 
gilvocarcin and jadomycin pathways indicated that both jadomycin A (21) and GV (19) 
biosynthetic pathways share a common oxidative route. The hypothesis was further 
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supported by the accumulation of similar metabolites when oxygenases (encoded by 
jadF, jadG and jadH) from the jadomycin pathway were inactivated (Scheme 1.17).(70, 
71) More interestingly, cross complementation of the ∆GilOI and ∆GilOIV mutant strains 
with JadH and JadF, respectively, restored the production of gilvocarcin. However, 
ΔgilOII/jadG complementation did not restore GV production.(69) Despite the extensive 
studies, the enzymatic events and actual substrate for C–C bond cleavage remained 
obscure.  
Rohr et al. inactivated several other genes as a means of delineating the 
gilvocarcin biosythtic pathway. The ∆GilR mutant accumulated pregilvocarcin V (66), a 
hemiacetal,(72) indirectly proving that gilvocarcin biosynthesis proceeds via an 
aldehyde-acid intermediate (59) as opposed to alternatives in the literature (example, the 
one shown is scheme 1.15) that suggested diacid intermediates for the GV and related 
pathways.(73-75) Inactivation of GilGT completely abolished the production of GV but 
accumulated defuco-GV (48) clearly indicating that GilGT was involved in the C-
glycosylation.(76) Additionally, inactivation of gilM did not accumulate any product 
suggesting gilM to be critical for the pathway, although its exact role is not known. 
Deletion of a putative methyltransferase, encoded by gilMT also did not accumulate any 
product.  
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Scheme 0.16 Previously proposed pathway for GV biosynthesis. 
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Scheme 0.17 Biosynthetic pathway of jadomycins A and B. 
D-fucofuranose is a unique deoxysugar and is rarely found in glycosylated natural 
products. Inactivation of the putative deoxysugar 4-ketoreductase gene gilU resulted in 
the accumulation of a new GV derivative, 4′-hydroxy-GV (70), with an improved 
biological activity.(77) GilU reduces the 4-keto group of 79 (Scheme 1.18) in a 
stereospecific manner to generate TDP-D-fucose, which further undergoes a yet unknown 
ring-contraction and glycosylation steps to yield the D-fucofuranose moiety of GV (81). 
 
Scheme 0.18 TDP-D-fucofuranose biosynthesis. 
Very recently, Rohr and co-workers demonstrated a combinatorial biosynthetic 
enzymology approach leading to the enzymatic total synthesis of defuco-gilvocarcin M 
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(45), a model compound with the complete gilvocarcin chromophore.(78) The total 
enzymatic synthesis of 45 from acetyl-CoA and malonyl-CoA, with systematic variations 
of the enzyme mixtures, revealed a simplified hypothetical pathway (Scheme 1.19) 
confirming that prejadomycin (55) and dehydrorabelomycin are intermediates in the GV 
biosynthesis pathway. Several attempts of crossfeeding studies and in vitro enzyme 
reactions failed to convert UWM6 (53) to 45, confirming that 53, which was previously 
considered the first post PKS tetracyclic intermediate, is a shunt product. However, when 
JadF, the homologue of GilOIV was added to the PKS enzyme mix, 55 was isolated, 
leading to a new hypothesis that GilOIV may actually act on angucyclic substrates (82) 
that are still bound to the ACP to directly give 55. A spontaneous hydrolysis and 
decarboxylation of 82 would then result in 53. Finally, the study revealed that 
GilOIV/JadF do not function as oxygenases but catalyze a 2,3-dehydration reaction along 
with PKS-release and therefore are crucial enzymes that bridge PKS and post-PKS 
reactions. The in vitro enzymatic analysis also showed that GilOI is an anthrone 
oxygenase responsible for the 12-hydroxylation of 55. 
 
Scheme 0.19 A revised gilvocarcin biosynthetic pathway. 
1.5. Summary 
Nature creates a multitude of natural products also known as secondary 
metabolites with a diverse range of activities. Polyketides are complex small molecules 
that come from a variety of biological sources, mostly from microbes. Polyketides are 
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known to possess a vast array of pharmaceutical activities. Because of the high 
pharmaceutical significance, there have been constant efforts to synthesize these complex 
scaffolds. Total synthesis of natural products remains the most vital tool to provide 
pharmacologically improved molecules, but it sometimes becomes challenging because 
of structural complexities within the molecules. An alternative to this approach is 
mutasynthesis or chemo-enzymatic synthesis, which utilizes synthetic chemistry to 
construct analogues of the intermediates in the pathway, leaving the remaining, more 
difficult, alterations to be accomplished by the producing organism or enzymes. To be 
able to construct the bioactive polyketides, a deeper knowledge of their biosynthesis is 
vital. Our lab has been investigating gilvocarcin V (19) biosynthesis for quite a few years 
with focus on developing novel analogues either through mutasynthesis or a 
combinatorial biosynthetic approach for structure activity relationship (SAR) studies. 
Isolation of complete gene clusters followed by labeling studies, gene inactivation, and 
cross feeding analyses has helped to identify the functions of the PKS gene products 
along with some post-PKS enzymes. However, the exact biosynthetic intermediates and 
sequence of reactions remained elusive. A recent enzymatic total synthesis of 
defucogilvocarcin M (45) provided deeper insights into its biosynthesis and paved the 
way for further characterization of critical post PKS enzymes.(78)  
1.6. Specific aims 
The objectives of this study were to identify the intermediates in the biosynthetic 
pathway of GV and to elucidate the functional role of involved post-PKS tailoring 
enzymes along with their substrate specificities; the prerequisite for a successful chemo-
enzymatic approach towards novel GV analogues. To accomplish this goal, the following 
specific aims were addressed:  
Specific aim 1 was to investigate the roles of a putative methyltransferase, GilMT 
and an unknown enzyme GilM.  
Synthesis of the proposed intermediate and in vitro enzyme reactions revealed 
GilMT as an S-adenosylmethionine (Ado-met) dependent O-methyltransferase and GilM 
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as an Ado-met bound reductive methyltransferase that acts on the monomethylated 
quinone and converts it into defuco-pregilvocarcin. GilM is unique in its functionality as 
it mediates its reducing capabilities by coupling with GilR, an FAD-dependent 
oxidoreductase. GilM utilizes reduced flavin produced in the GilR reaction and then 
regenerates FAD for the next catalytic cycle. 
Specific aim 2 was to delineate C–C bond cleavage in gilvocarcin biosynthesis.  
 Through in vitro studies, the enzyme responsible for the C–C bond cleavage and 
the exact substrate were revealed. The crucial C–C bond cleavage was attributed to 
GilOII. The FADH2 dependent GilOII catalyzes sequential three step reactions: the initial 
5-hydroxylation and the following Baeyer-Villiger oxidation. Finally, GilOII aided the 
ring opening completing the oxidative cascade. In the process JadG, a GilOII homologue 
from jadomycin pathway was also studied. JadG was also shown to catalyze C–C bond 
cleavage via the same 3-step oxidation. 
Specific aim 3 was to explore subsrate specificities for GilM and GilMT. 
A small series of structural analogues of the intermediate of the gilvocarcin 
pathway were generated via chemical synthesis and were fed to the mixture of the post-
PKS enzymes. The reaction mixtures were analyzed to establish the diversity of 
substrates tolerated by the enzymes. Through chemoenzymatic synthesis we proved that 
the two critical downstream enzymes, GilM and GilMT, are flexible enough to 
accommodate analogues with small variations.  
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Chapter 2. Investigating roles of a putative methyltransferase GilMT and an 
unknown enzyme GilM. 
The role of many of the post PKS gene products have been assigned based on 
gene inactivation, cross-feeding, and labeling studies.(39, 49, 69, 72, 78-80) Most of the 
genes of the three known biosynthetic clusters(81) of this group have been assigned to 
certain enzymatic activities allowing us to predict the biosynthetic steps en route to 
gilvocarcins (Scheme 1.17). Despite rigorous efforts, most of the post PKS gene 
functions remained unclear. The major hurdle in completely elucidating the pathway is 
the lack of isolable substrates.  
Among other downstream genes, gilM (encoding an enzyme of unknown 
function) and gilMT (encoding a methyltransferase) appear to be crucial for the 
biosynthesis of gilvocarcin and were proposed to be involved in O-methylation reactions. 
However, the exact functions of their genes products, GilM and GilMT, remained 
obscure. The mutant strains created by deletion of their corresponding genes did not 
accumulate any isolable metabolites, and thus provided no clue regarding their potential 
substrates and thus providing no insight into the structure of key biosynthetic 
intermediates. 
2.1. Design and synthesis of the model substrate 
A recent combinatorial biosynthetic approach based on enzymology led to the 
enzymatic total synthesis of defuco-gilvocarcin M (45) from acetyl-CoA and malonyl-
CoA, a model compound with the complete gilvocarcin chromophore. Moreover,  
systematic variations of the enzyme mixtures revealed a greatly simplified hypothetical 
pathway (Scheme 1.19) suggesting that 2-aryl-5-hydroxy-1,4-naphthoquinone-3-
carboxylic acid (83) is likely the product of the critical oxidative C–C bond cleavage and 
thereby a key intermediate of the gilvocarcins. The results also suggested that only three 
more enzymes, namely GilM, GilMT and GilR, were necessary to finish the biosynthesis 
of 45. To confirm this hypothesis and fully enlighten the “biosynthetic black box”, a 
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potential model substrate, 2-aryl-5-hydroxy-1,4-naphthoquinone (84) was synthesized 
and subsequently used to interrogate the function of GilM and GilMT. 
 
 
Scheme 2.1 Retrosynthetic analysis of model compound 84. 
 
 
Scheme 0.1 Synthesis of 84. 
2.2. Results and discussions 
The model compound 84 could be prepared by sewing together 85 and 86 via 
Stille coupling (Scheme 2.1). Synthesis of compound 86 began with commercially 
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available dimethyl anisole (87).(82) Bromination with NBS and benzoyl peroxide 
provided mono bromo benzyl derivative. A sequential hydroxylation followed by 
oxidation with PCC afforded 88 in 60% yield from 87.(82) Removal of the methoxy 
group was achieved in 60% yield by treatment with BBr3 at r.t., followed by acidic 
hydrolysis. Protection of the aldehyde as a cyclic acetal and the phenolic OH as 
methoxylmethyl ether provided 90. An ortho-metalation with tributyltinchloride yielded 
the required stannane 84 in 88% yield.(83) 2-bromonaphthoquinone (85) was prepared 
from juglone using the reported protocol.(84) A facile Stille coupling between 85 and 86 
provided 91. 91 was then exposed to harsh acidic conditions (2.4 M HCl in CH3CN) for 4 
min to provide fully unprotected 2-aryl-1,4-naphthaquinone 84 in 74% yield.(83) 
With a potential substrate in hand, both gilM and gilMT genes were cloned into 
pET28a and expressed in E. coli to yield soluble proteins that were purified to near 
homogeneity. Synthetic 84 when incubated with purified GilM produced a complex 
mixture (Fig. 2.1, trace C). In contrast, HPLC-MS analysis of 84 with GilMT and S-
adenosylmethionine (SAM) revealed a decrease in the amount of substrate and formation 
of a new product (Fig. 2.1, trace E). In the absence of SAM, no product was formed (Fig. 
2.1, trace D). The GilMT product was isolated and characterized using NMR and HRMS. 
The analysis revealed the product as mono-methylated derivative 92. Nuclear Overhauser 
enhancement (nOe) studies further confirmed that the hydroxyl group of the phenyl ring 
of substrate 84 was methylated. 
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Figure 0.1 HPLC traces of the enzymatic reactions with 2-aryl-1,4-naphthaquinone (84): (A) 
standard 2-aryl-1,4-naphthaquinone (84); (B) standard defuco-gilvocarcin M (7); (C) 84 + GilM; 
(D) 84 + GilMT; (E) 84 + GilMT+ SAM; (F) 84 + GilMT + GilM + SAM; (G) 84 + GilMT + 
GilM + GilR + SAM. 
When compound 84 was incubated with both GilM and GilMT along with SAM, 
a new product along with 92 accumulated (Figure 2.1, trace F). The new compound was 
identified as defuco-pregilvocarcin M (52) by NMR experiments (1H NMR, HSQC). 
Adding GilR led to the accumulation of defuco-gilvocarcin M (45) (Figure 2.1, trace G), 
further confirming the structure of the GilM/MT product as 52. In total the results 
suggested that GilMT is a typical SAM-dependent O-methyltransferase, while GilM was 
responsible for the reduction of the quinone moiety necessary for the observed second O-
methylation. BLAST analysis (85, 86) revealed GilM to have low similarity (34-37% 
sequence identity) to nucleotidyl-S-transferases such as thiopurine-S-methyltransferases 
from Rhodococcus equi or Mycobacterium avium as well as to benzoquinone 
methyltransferases from Mycobacterium tuberculosis (33% sequence identity). The 
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translated amino acid sequence of GilM contains VLDLGCGLG as residues 49-57, 
which appear to be a SAM binding motif (generally hh(D/E)hGXGXG, where h 
represents a hydrophobic residue). Thus, it remained unclear at this point whether GilMT 
or GilM catalyzes the second O-methylation. To solve this ambiguity, product 92 from 
the GilMT reaction was used as a substrate for GilM in the presence of SAM. The 
reaction accumulated 52, suggesting that GilM not only mediates reduction of the 
quinone but also catalyzes the second O-methylation. Surprisingly, the GilM reaction 
seemed to convert 92 to 52 even in absence of SAM, which prompted us to further 
investigate GilM for any bound SAM cofactor.  
GilM catalyzes reductive methylation without any external cofactor. However, the 
BLAST analysis showed a very vague similarity to thiopurine-S-methyltransferases. To 
analyze any bound cofactor, the enzyme was boiled for 5 minutes and centrifuged (12000 
×g, 5 min). The supernatant was then subjected to LC-MS analysis. A linear gradient of 
acetonitrile and 0.1% formic acid-water (solvent A = 0.1% formic acid-H2O; solvent B = 
acetonitrile; 0-15 min 25% B to 100% B; 16-24 min 100% B; 25-26 min 100% to 25% B; 
27-29 min 25% B) with flow rate of 0.5 mL/min was used to separate the compounds in a 
Waters Symmetry C18 (4.6 × 250 mm, 5μm) column. The supernatant showed UV-
absorption at 260, typical of an adenosine spectrum, indicated co-purified SAM. To 
further verify presence of loosely bound S-adenosylmethionine, standard solution of S-
adenosylmethionine was prepared in 50 mM phosphate buffer and was used in parallel 
for comparison. GilM was found to be co-purifying with S-adenosylmethionine (Figure 
2.2). 
. 
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Figure 0.2 HPLC traces of the released cofactor: (A) standard S-adenosylmethionine; (B) 
Cofactor released from GilM; (C) S-adenosylmethionine boiled for 5 min. 
To further analyze the reaction sequence catalyzed by GilM, compound 92 was 
incubated with GilM and the reaction was studied at different time points (Figure 2.3). 
With stoichiometric enzyme quantities, the substrate was 80% converted into the product 
after 15 minutes (Figure 2.3, trace D). When the reaction was analyzed by reversed phase 
HPLC-MS in 3-5 min intervals, a new peak (93) appeared with shorter retention time 
than the overall product 52 (Figure 2.3). Although NMR analysis of 93 was impossible 
due to its instability, LC-MS analysis suggested it to be demethyl-defuco-pregilvocarcin 
M (m/z 323 [M-H]−). To prove that 93 was an intermediate en route to 52 and not a shunt 
product, 93 was incubated with GilM, and, as anticipated, was rapidly converted to 52 
(Figure 2.3, trace F). Overall, the results showed that GilM catalyzes a sequence of three 
reactions: (i) quinone reduction, (ii) hemiacetal formation and (iii) O-methylation, to 
construct the tetracyclic core of the gilvocarcins. 
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Figure 0.3 HPLC traces of the enzymatic reactions with 92: (A) standard 92; (B) 92 + GilM + 
SAM + 5 min; (C) 92 + GilM + SAM + 10 min; (D) 92 + GilM + SAM + 15 min; (E) 
intermediate (93) isolated from HPLC (mixture of closed and open form); (F) 93 + GilM. 
39 
 
 
Figure 0.4 R and M genes in gilvocarcin, ravidomycin and chrysomcin gene clusters. 
 
Figure 0.5 HPLC traces of the enzymatic reactions with 92: (A) standard 92; (B) standard 
defuco-gilvocarcin M (45); (C) 92 + GilM; (D) 92 + GilM + GilR; (E) 92 + GilM + GilR + SAM. 
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The only remaining question was the regeneration of GilM after reduction of the 
quinone. Interestingly, the respective GilM-activity in the biosynthetic pathways of other 
structurally related compounds, chrysomycin A and ravidomycin V, is encoded on the 
same gene as the oxidoreductase GilR-activity,(81) while in the gilvocarcin pathway, 
gilM and gilR are two separate genes (Figure 2.4).(49) This prompted us to propose that 
GilM could be working in conjunction with GilR, an FAD dependent oxidoreductase that 
catalyzes the very last step in gilvocarcin biosynthesis by converting pregilvocarcin to 
gilvocarcin, but also was shown to convert sugar free defuco-pregilvocarcins.(38, 87) We 
hypothesized that GilM utilizes the reduced flavin generated in the GilR reaction to 
reduce the quinone thereby regenerating oxidized flavin for the next catalytic cycle. To 
validate this hypothesis, compound 92 was incubated with GilM and GilR (Figure 2.5). 
The assistance of GilR for the reducing capabilities of GilM was established by 
measuring the amounts of the products formed in the reactions. Catalytic amounts of 
GilM alone accumulated mostly starting material along with minor production of 52 
(Figure 2.5, trace C). In the absence of SAM, GilM and GilR accumulated a new peak 
(Figure 2.5, trace D) that corresponds to demethyl-defuco-gilvocarcin M(88) (94, m/z 321 
[M-H]−). Adding SAM to the GilM-GilR reaction mixture led to the accumulation of 7 
(Figure 2.5, trace E). A 10-fold increase in the formation of 45 in the GilM-GilR reaction 
versus using GilM alone confirmed that GilM works synergistically with GilR. 
Overall, these results described here allowed us to fully prove the post-PKS 
reaction sequence of the gilvocarcin biosynthetic pathway as shown in Scheme 2.3. The 
fact that the easy to synthesize compound 84 is an intermediate of the gilvocarcin 
pathway opens up future possibilities of generating gilvocarcin analogues through 
chemo-enzymatic synthesis or mutasynthesis,(89, 90) thus coupling the power of 
chemical synthesis with metabolic engineering. 
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Scheme 0.2 Key follow-up sequence of events involving GilMT and GilM reactions en route to 
defucogilvocarcin M (45) and gilvocarcin M (46). 
2.3. Experimental 
Section A: General Information 
General Remarks: 1H and 13C spectra were recorded using Agilent instruments (1H 
frequencies 300, 400 and 500 MHz, corresponding 13C frequencies are 75, 100, 125 
MHz, respectively). Chemical shifts are quoted in parts per million (ppm) relative to 
TMS. J values are recorded in Hz. A photodiode array detector (Waters 2996) along with 
a Micromass ZQ 2000 mass spectrometer (Waters Corporation) equipped with an 
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electrospray ionization (ESI) probe was used to detect the molecular ions and analyze the 
compounds. 60-200 mesh silica gel was used for flash column chromatography. Thin 
layer chromatography was carried out using aluminum backed plates coated with silica 
gel. The plates were visualized under UV light at 254 nm and /or vanillin stain. Rf values 
were obtained by elution in the stated solvent ratios (v/v). All small-scale dry reactions 
were carried out under Nitrogen using standard syringe-septum technique. 
Section B: Synthetic protocols 
3-Methoxy-5-methylbenzaldehyde (88): This was prepared in 3 steps. 
 
 To a magnetically stirred solution of the dimethyl anisole (500 mg, 3.68 mmol) in 
CCl4 (40 mL) was added NBS (622 mg, 3.5 mmol) and benzoyl peroxide (10 mg). After 
refluxing for 1h, the reaction mixture was filtered and the filtrate was successively 
washed with aqueous HCl (3 N), saturated aqueous NaHCO3, H2O and brine. The organic 
layer was dried over Na2SO4 and the solvent was evaporated to give a residue that was 
purified on a silica gel column (30% CH2Cl2–hexane, Rf = 0.56) to furnish the bromide 
(70%). 
To a stirred solution of the above bromide (2.15 g, 9.95 mmol) in acetone (60 mL) 
and H2O (100 mL) was added NaHCO3 (1.05 g, 12.5 mmol). The reaction mixture was 
refluxed for 4h then cooled to r.t. and extracted with EtOAc (3×50 mL). The combined 
organic layer was washed with brine and dried (Na2SO4). Evaporation of the solvent and 
purification of the residue on a silica gel column (20% EtOAc–hexane, Rf = 0.2) 
furnished the alcohol (86%).(89) 
To a stirred suspension of pyridinium chlorochromate (2.0 g, 14.4 mmol) and 
silica gel (2.0 g) in anhydrous CH2Cl2 (10 mL) was added a solution of the above alcohol 
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(1.3 g, 9.6 mmol) in CH2Cl2 (5 mL). After stirring the reaction mixture for 1h at r.t., it 
was filtered through a small silica gel column. The column was eluted with excess 
CH2Cl2 and the solvent was evaporated under reduced pressure to furnish the 
benzaldehyde as oil (quant.) (40% CH2Cl2–hexane, Rf = 0.45). 1H NMR (CDCl3, 300 
MHz) δ 9.90 (s, 1H), 7.25 (bs, 1H), 7.18 (bs, 1H), 6.97 (bs, 1H), 3.82 (s, 3H), 2.38 (s, 
3H); 13C NMR (CDCl3, 75 MHz) δ 192.3, 160.1, 140.4, 137.7, 124.4, 122.2, 109.5, 55.6, 
21.5.  
3-Hydroxy-5-methylbenzaldehyde (89) 
 
 1M BBr3 in CH2Cl2 (6.6 mL, 6.6 mmol) was added dropwise to a stirred solution 
of 88 (500 mg, 3.3 mmol) in anhydrous CH2Cl2 (10 mL) under nitrogen at r.t. After 
stirring for 2h, 3 mL of each HCl and AcOH were added and reaction mixture was 
refluxed for 10h. The reaction was cooled, diluted with H2O and extracted with CH2Cl2. 
The combined organic layer was dried over Na2SO4 and the solvent was evaporated to 
give a residue that was purified on silica gel (20% EtOAc-hexane, Rf = 0.25) to give 
deprotected derivative as yellowish solid in 60% yield.(91) 1H NMR (CD3OD, 300 MHz) 
δ 9.76 (s, 1H), 7.09 (bs, 1H), 7.04 (bs, 1H), 6.87 (bs, 1H), 2.27 (s, 3H); 13C NMR 
(CD3OD, 75 MHz) δ 194.2, 158.8, 141.4, 138.9, 123.5, 113.1, 54.7, 21.3.  
2-(3-Methoxymethoxy-5-methylphenyl)-1,3-dioxane (90): This protected 
benzaldehyde was prepared in 2 steps. 
(a) 2-(3-Hydroxy-5-methylphenyl)-1,3-dioxane 
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A mixture of 89 (200 mg, 1.5 mmol), 1,3-propanediol (0.16 mL, 2.2 mmol) and 
TsOH.H2O (6 mg, 0.03 mmol)  in toluene was refluxed with the azeotropic removal of 
H2O. After starting material was consumed completely, the reaction mixture was cooled 
and the solvent was removed under pressure to give a residue. The crude residue was 
purified on silica (EtOAc-hexane, Rf = 0.32) to give the protected aldehyde(88) as a white 
solid in 75% yield. 1H NMR (CDCl3, 300 MHz) δ 6.84 (bs, 1H), 6.70 (bs, 1H), 6.49 (bs, 
1H), 6.45 (bs, 1H), 5.39 (s, 1H), 4.27–4.21 (m, 2H), 3.99–3.92 (m, 2H), 2.22 (s, 3H), 
2.20–2.14 (m, 1H), 1.44–1.38 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 155.7, 139.6, 
139.4, 118.7, 116.8, 110.4, 101.7, 67.4, 25.8, 21.5; HRMS (+EI): Calc’d for C11H14O3: 
194.0943, observed: 194.0944. 
(b) 2-(3-Methoxymethoxy-5-methylphenyl)-1,3-dioxane (90) 
 
 To a stirred solution of the above phenyl acetal (165 mg, 0.85 mmol) and 
diisopropylethylamine (0.23 mL, 1.35 mmol) in anhydrous CH2Cl2 was dropwise added 
chloromethyl methyl ether (0.14 mL, 1.69 mmol) and the mixture was heated at 40 °C. 
After 24h, reaction mixture was washed with H2O and brine. The combined organic layer 
was dried over Na2SO4 and the solvent was removed under vacuum to give MOM 
ether(17) as colorless oil in 95% yield. 1H NMR (CDCl3, 300 MHz) δ 6.97 (bs, 1H), 6.82 
(bs, 1H), 5.42 (s, 1H), 5.15 (s, 2H), 4.26–4.20 (m, 2H), 3.98–3.89 (m, 2H), 3.44 (s, 3H), 
2.32 (s, 3H), 2.28–2.12 (m, 1H), 1.42–1.36 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 157.0, 
139.8, 139.3, 120.1, 117.2, 110.8, 101.4, 94.2, 67.3, 55.9, 25.8, 21.5; HRMS (+EI): 
Calc’d for C13H18O4: 238.1205, observed: 238.1204. 
(2-(1,3-dioxan-2-yl)-6-(methoxymethoxy)-4-methylphenyl)tributylstannane (86) 
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 The above MOM ether (300 mg, 1.26 mmol) was co-evaporated twice with 
anhydrous toluene and was dissolved in freshly dried hexane (10 mL). At 0 °C, n-BuLi 
(0.6 mL, 2.5M in hexane, 1.5 mmol) was added and the mixture was stirred for 30 min. A 
white precipitate indicates the formation of lithiated species. After 30 min, n-Bu3SnCl 
(0.5 mL, 1.89 mmol) was added and the mixture was further stirred for 30 min. It was 
then diluted with hexane-Et2O (1:1, v/v), followed by the addition of saturated aqueous 
NaHCO3. The mixture was stirred at 0 °C for 30 min. After separation, the aqueous layer 
was extracted twice with hexane-Et2O (1:1, v/v). The combined organic layers were 
washed with brine and dried over Na2SO4. The solvent was removed under vacuum and 
the residue was subjected to purification on silica to give the required stannane(83) (3% 
EtOAc-hexane, Rf = 0.5) as colorless oil (88%). 1H NMR (CDCl3, 300 MHz) 7.24 (bs, 
1H), 6.90 (bs, 1H), 5.38 (s, 1H), 5.11 (s, 2H), 4.26-4.21 (bs, 2H), 3.99 (bs, 2H), 3.45 (s, 
3H), 2.34 (s, 3H), 2.30-2.12 (m, 1H), 1.56-0.87 (m, 28H);  δ  13C NMR (CDCl3, 75 MHz) 
δ 161.9, 146.6, 140.3, 125.8, 120.6, 113.7, 102.5, 94.5, 67.4, 56.0, 29.4, 27.7, 26.0, 21.8, 
14.0, 12.4; HRMS (ESI): Calc’d for [C25H44O4Sn+H]+: 529.2339, observed: 529.2342. 
2-(2-(1,3-dioxan-2-yl)-6-(methoxymethoxy)-4-methylphenyl)-5-hydroxy-1,4-
napthaquinone (91)  
 
 To a solution of 2-Bromo-8-hydroxy-1,4-naphthaquinone 85 (96 mg, 0.38 
mmol), stannane 86 (200 mg, 0.38 mmol), and CuI (7.6 mg, 0.04 mmol) in THF (5 mL) 
was added a solution of Pd2(dba)3•CHCl3 (9.8 mg, 0.009 mmol) and PPh3 (10.5 mg, 0.04 
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mmol) in THF (1 mL). The mixture was heated at 75 °C for 12h. The mixture was cooled 
to 0 °C and diluted with EtOAc (25 mL). Saturated aqueous NaHCO3 (25 mL) was added 
and the mixture was stirred for 30 min. The layers were separated and the aqueous layer 
was extracted twice with EtOAc (50 mL). The combined organic layers were washed 
with brine and dried over Na2SO4. The solvent was removed under vacuum and the 
resulting residue was subjected to flash silica gel column chromatography to provide the 
coupled product(83) (35% EtOAc-hexane, Rf = 0.6) as orange solid (75%). 1H NMR 
(CDCl3, 400 MHz) δ 12.33 (s, 1H), 7.80 (dd, J = 8.5, 7.5 Hz, 1H ), 7.61 (dd, J = 7.5, 1 
Hz, 1H), 7.39 (bs, 1H), 7.36 (dd, J = 8.5, 1 Hz, 1H), 7.18 (bs, 1H), 6.99 (s, 1H), 2.43 (s, 
3H); 13C NMR (CDCl3, 100 MHz) δ 190, 5, 184.5, 162.5, 156.1, 147.5, 142.1, 138.7, 
137.7, 137.3, 133.5, 126.4, 124.8, 124.7, 123.3, 119.2, 116.4, 21.1. 
3-hydroxy-2-(5-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-5-
methylbenzaldehyde (84) 
 
 To 91 (60 mg, 0.14 mmol) in a 250 mL flask at r.t. was added a solution of 
concentrated HCl (2 mL) in 10 mL CH3CN. The mixture was stirred for 4 min and then 
was quenched with NaHCO3 (60 mL) followed by addition of EtOAc (50 mL). After 
separation of the layers, the aqueous layer was extracted with EtOAc twice. The 
combined organic layers was washed with brine, dried over Na2SO4 and the solvent was 
removed under vacuum. The resulting residue was subjected to purification by flash silica 
gel column chromatography to provide the desired product(83) (35% EtOAc-hexane, Rf = 
0.25) as orange solid (74%). 1H NMR (acetone-d6, 500 MHz) δ 12.06 (bs, 1H), 9.90 (s, 
1H), 7.80 (dd, J = 8.5, 7.5 Hz, 1H ), 7.61 (dd, J = 7.5, 1 Hz, 1H), 7.39 (bs, 1H), 7.36 (dd, 
J = 8.5, 1 Hz, 1H), 7.18 (bs, 1H), 6.99 (s, 1H), 2.43 (s, 3H); 13C NMR (acetone-d6, 100 
MHz) δ 193.0, 190.5, 184.5, 162.5, 156.1, 147.5, 142.1, 138.7, 137.7, 137.3, 133.5, 
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126.4, 124.8, 124.7, 123.3, 119.2, 116.4, 21.1; HRMS (+EI): Calc’d for C18H12O5: 
308.0685, observed: 308.0686. 
Section C: Expression and Purification of Enzymes 
gilM, gilMT, and gilR genes were expressed using pET28a(+) expression 
constructs in E. coli BL21 (DE3) with an N-terminal polyhistidine tag. A single colony 
was transferred to 10 mL LB supplemented with 50 μg/mL kanamycin and grown at 37 
°C and 250 rpm for 5h. Subsequently, 500 mL LB supplemented with 50 μg/mL 
kanamycin was inoculated with 5 mL of the culture and was grown at 37 °C until OD600 
reached to 0.5. Gene expression was induced with isopropyl-β-D-1-thiogalactopyranoside 
(IPTG, 0.2 mM final concentration) and the culture was allowed to grow at 18 °C for 
16h. The cell pellets were collected by centrifugation (4000 × g, 15 min) and were 
washed twice with 20 mL of lysis buffer (50 mM KH2PO4, 300 mM KCl, 10 mM 
imidazole, pH 8.0). The cells were lysed using a French Press and the crude soluble 
enzyme fractions were collected through centrifugation (16000 × g, 1h). The crude 
enzymes were loaded onto a Talon metal affinity resin (BD Biosciences) column and 
were washed three times with lysis buffer. The enzymes were then eluted with elution 
buffer (50 mM KH2PO4, 300 mM KCl, 250 mM imidazole, pH 8.0). The purified 
proteins were concentrated using an Amicon Ultra centrifugal filter (Millipore Corp.) and 
stored as 25% glycerol stocks at -20 °C. The concentration of protein was determined by 
the Bradford method using a calibration curve of the known concentrations of BSA. The 
concentrations for GilM, GilMT and GilR were found to be 6.7, 12.5 and 2.4 mg mL-1 
respectively. 
Section D: Cofactor Analysis of GilM 
GilM catalyzes reductive methylation without any external cofactor. However, the 
BLAST analysis showed a very vague similarity to thiopurine-S-methyltransferases. To 
analyze any co-purified cofactor, the enzyme was boiled for 5 minutes and centrifuged 
(12000 ×g, 5 min). The supernatant was then subjected to LC-MS analysis. A linear 
gradient of acetonitrile and 0.1% formic acid-water (solvent A = 0.1% formic acid-H2O; 
solvent B = acetonitrile; 0-15 min 25% B to 100% B; 16-24 min 100% B; 25-26 min 
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100% to 25% B; 27-29 min 25% B) with flow rate of 0.5 mL/min was used to separate 
the compounds in a Waters Symmetry C18 (4.6 × 250 mm, 5μm) column. The supernatant 
showed UV-absorption at 260, typical of adenosine spectrum. To further verify presence 
of loosely bound S-adenosylmethionine a standard solution of S-adenosylmethionine was 
prepared in 50 mM phosphate buffer and was used in parallel for comparison. GilM was 
found to be co-purifying with S-adenosylmethionine. 
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Figure 0.6 HPLC traces of the released cofactor: (A) standard S-adenosylmethionine; 
(B) Cofactor released from GilM; (C) S-adenosylmethionine boiled for 5 min. 
Section E: Kinetic Profile 
GilM 
A typical reaction mixture (50 μM) composed of substrate (92), 50 mM phosphate 
buffer, 20 μM enzyme (final concentration) was incubated at 25 °C. After 5 min reaction 
was extracted twice with EtOAc (300 μl) and combined organic layers were dried under 
vacuum. The residue was then dissolved in 50 μl acetonitrile and 20 μl was injected onto 
HPLC following the protocol described in Section D. The amount of product formed was 
estimated by plotting the peak area in the standard calibration curve. The data resulting 
from incubating 7 different substrate concentrations with enzyme were fit to the Michael-
Menten equation with nonlinear regression. kcat and KM values were calculated using 
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GraphPad Prism 5.0. The analysis was done in triplicate and the average was taken. The 
analysis yielded a kcat of 0.02930 and a KM of 35.38μM.  
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GilMT 
A typical reaction mixture (100 μM) composed of substrate (84), 50 mM 
phosphate buffer, S-adenosylmethionine (excess), 13.7 μM GilMT (final concentration) 
was incubated at 25 °C for 5–15 min to optimize the analysis condition. The kinetic 
profile for GilMT could not be generated due to solubility issues. The substrate 
concentration above 1 mM resulted in substrate precipitation while less enzyme 
concentration failed to produce substantial amount of product to be monitored by HPLC.  
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Section F: In vitro enzymatic reactions 
Enzymatic synthesis of 2-(5-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-3-
methoxy-5-methylbenzaldehyde (92) 
 
 
An assay mixture (5 mL) composed of phosphate buffer (pH 6.5, 50 mM), 
substrate 84 (100 μM), S-adenosylmethionine (excess), and GilMT (10 μM) was 
incubated at 30 °C for 12h. The reaction was extracted with EtOAc (2 × 10 mL). The 
organic solvent was dried at low pressure and the crude product was dissolved in CH3CN. 
The product showed UV-absorbance at 420 and was purified through HPLC using the 
conditions as described in Section D. The reaction produced the desired methylated 
product in 40% yield. 1H NMR (CDCl3, 400 MHz) δ 12.03 (s, 1H), 9.85 (s, 1H), 7.64-
7.60 (m, 2H), 7.33 (bs, 1H), 7.28 (dd, J = 7.5, 2 Hz, 1H), 7.05 (bs, 1H), 6.82 (s, 1H), 3.77 
(s, 3H), 2.48 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 191.7, 190.2, 183.3, 161.5, 157.3, 
147.5, 141.6, 137.1, 136.4, 135.8, 132.7, 125.7, 124.2, 119.8, 117.7, 115.6, 56.3, 21.8; 
HRMS (+EI): Calc’d for C19H14O5: 322.0841, observed: 322.0850. 
Enzymatic synthesis of defuco-pregilvocarcin M (52) 
An assay mixture (1 mL) composed of phosphate buffer (pH 6.5, 50 mM), 
substrate 92 (100 μM), S-adenosylmethionine (excess), and GilM (8 μM) was incubated 
at 30 °C for 4h. The reaction was extracted with EtOAc (2 × 2 mL). The organic solvent 
was removed at low pressure and the crude product was dissolved in CH3CN. The 
cyclized product showed a sharp absorbance at 375 nm and was purified through HPLC 
(conditions as described in Section D). The reaction produced the desired product in 60% 
yield. HRMS (+EI): Calc’d for C20H18O5: 338.1154, observed: 338.1160. 
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Table 2.1 1H and HSQC data for defuco-pregilvocarcinM (52) in CDCl3 (500 MHz, relative to 
internal TMS, J in Hz). 
Position       1H NMR    Multiplicity(Hz)       HSQC 
1-OH 9.43 S  
2 6.88 d (1)       113.6 
3 7.38 dd (8.5, 7.5)       125.4 
4 7.83 dd (8.5, 1)  
6 6.40 d (6.5)       93.1 
6-OH 3.02 d (6.5)  
7 6.89 d (2)       119.4 
8-CH3 2.41 S       21.8 
9 6.86 Bs       111.2 
10-OCH3 3.97 S       56.0 
11 8.04 S       103.6 
12-OCH3 4.08 S       56.2 
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Enzymatic synthesis of demethyl-defuco-pregilvocarcin M (93) 
 
 
An assay mixture (50 μl) composed of phosphate buffer (pH 6.5, 50 mM), 
substrate 92 (0.8 μM), and GilM (0.04 μM) was incubated at 30 °C for 5 min. The 
reaction was extracted with EtOAc (2 × 2 mL). The organic solvent was dried at low 
pressure and the crude product was dissolved in CH3CN. The solution was injected onto 
HPLC (conditions described in Section D). The reaction produced the desired 
intermediate in 10 % yield. HRMS (ESI): Calc’d for [C19H16O5-H]- 323.0919, observed: 
323.0919. 
Enzymatic synthesis of demethyl-defuco-gilvocarcin M (94) 
 
 
An assay mixture (100 μl) composed of phosphate buffer (pH 6.5, 50 mM), 
substrate 92 (2 μM), GilM (0.1 μM) and GilR (0.2 μM) was incubated at 30 °C for 1h. 
The reaction was extracted with EtOAc (2 × 2 mL). The organic solvent was dried at low 
pressure and the crude product was dissolved in CH3CN. The solution was injected onto 
HPLC (conditions described in Section D). The reaction produced the desired product in 
31 % yield. HRMS (+EI): Calc’d for C19H14O5 322.0841, observed: 322.0846. 
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Chapter 3. Investigating C–C bond cleavage in the gilvocarcin biosynthetic pathway 
C–C bond cleavages initiate one of the most significant structural rearrangements 
in the biosynthesis of many natural products, through which numerous unique scaffolds 
are generated. Most of these cleavage reactions are also crucial for the biological activity 
of the natural products also (e.g., mithramycin, aflatoxin). Thus, great attention has been 
devoted to identifying the relevant enzymes and cleavage mechanisms. One of the 
important examples is found during the biosynthesis of gilvocarcins.  
It has been proven that the early biosynthetic steps generate an angucyclinone 
intermediate (e.g., prejadomycin/homo-prejadomycin 55/56, dehydrorabelomycin 73; 
Schemes 3.1) that subsequently undergoes a complex structural rearrangement via an 
oxidative C5–C6 bond cleavage to form the benzonaphthopyranone skeleton of the 
gilvocarcins.(49, 78, 79, 92) Another intriguing group of natural products, the jadomycins 
(e.g., 21 and 78), are believed to share their initial biosynthetic pathway including the 
oxidative rearrangement reaction.(69) To date, however, it has not been unambiguously 
proven at which exact step and by which mechanism these oxidative rearrangements take 
place. In this chapter, we unambiguously confirmed that GilOII (JadG for the jadomycin 
pathway) is the sole enzyme responsible for this oxidative C–C bond cleavage, and on the 
basis of the structure of an isolated pivotal intermediate, we were also able to propose a 
mechanism for this reaction.  
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Scheme 0.1 Representative members of the gilvocarcin and jadomycin groups of natural products 
sharing common biosynthetic intermediate, prejadomycin (55). 
3.1. Results 
A recent report on the enzymatic total synthesis of defucogilvocarcin M (45) 
confirmed that only four enzymes, namely oxygenase GilOII, methyltransferase GilMT, 
methyltransferase/reductase GilM, and oxidoreductase GilR are needed to convert the 
angucyclinone intermediate dehydrorabelomycin (73) to 45.(78)  
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Scheme 0.2 Sequence of events en route to defucogilvocarcin M. 
GilR is an FAD dependent oxidoreductase that catalyzes the very last step in 
gilvocarcin biosynthesis by converting pregilvocarcin to gilvocarcin, but also was shown 
to convert sugar free defuco-pregilvocarcins.(30, 69)   GilMT, an S-adenosylmethionine 
dependent O-methyltransferase, works on the intermediate 84, plausibly derived from the 
oxidative cleavage of dehydrorabelomycin (73). A subsequent sequence of reactions 
catalyzed by the S-adenosylmethionine dependent reductive O-methyltansferase, GilM, 
then generates the tetracyclic hemiacetal core, defucopregilvocarcin M (52), prompting 
us to impute the C-C bond cleavage reaction to GilOII. However, it remained unclear 
whether GilOII can catalyze the crucial C-C bond cleavage reaction alone or whether 
some support by one or more of the downstream enzymes were needed. Thus, we 
interrogated reactions of dehydrorabelomycin (73) with individual enzymes and a 
cocktail of downstream enzymes. GilOII, GilMT, GilM and GilR were expressed in E. 
coli and purified as His6-tagged proteins following a procedure described earlier.(78) 
Substrate 73 was prepared enzymatically from prejadomycin (55), a proven intermediate 
of both the gilvocarcin M and the jadomycin biosynthetic pathways as well as of many 
other anguclycines, which was isolated from a ΔgilOI mutant strain S. lividans TK24 
(cosG9B3–OI¯) following the reported procedure (see experimental section).(69) 
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As anticipated, the bi-functional enzyme GilM alone did not react with 73. GilMT 
alone reacted with 73 unexpectedly, yielding three different compounds (95–97), the 
major product was dimethyldehydrorabelomycin (95), and the other two minor products 
were identified as monomethylated dehydrorabelomycins 96 and 97 (Figure 3.1 trace D, 
Scheme 3.3). The low yields confirmed our prior findings that GilMT normally acts after 
the C–C bond cleavage on aldehyde intermediate 84.(92) Neither 95, 96 nor 97 were 
converted to defucogilvocarcin M (45) when treated with a mixture of GilOII, GilM, 
GilMT and GilR, proving that the C–C bond cleavage reaction requires a nonmethylated 
substrate, while 73 with a cocktail of GilOII, GilMT and GilM did accumulate defuco-
pregilvocarcin M (Figure 3.1, trace C). 
Investigating GilOII  
The reaction of 73 with GilOII alone resulted in consumption of all the starting 
material, but unexpectedly, no product was seen. After careful screening of different 
cofactors (FMN, FAD, NADH, NADPH) and cofactor regeneration enzymes, we found 
the correct conditions by incubating 73 with GiOII, FAD, and NADPH and adding E. coli 
flavin reductase (Fre), which is known to regenerate FADH2 from FAD using NADPH, 
and an NADPH-regeneration system containing glucose-6-phosphate and glucose-6-
phosphate dehydrogenase that maintained a constant supply of NADPH in the reaction. 
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Figure 0.1 HPLC traces of the enzymatic reactions: A) standard dehydrorabelomycin (73), B) 73 
+ GilOII + GilMT + GilM + GilR producing defucogilvocarcin M (45), C) 73 + GilOII + GilM + 
GilMT producing defucopregilvocarcin M (52), D) 73 + GilMT. 
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Scheme 0.3 Enzymatic reaction of dehydrorabelomycin (73) with GilMT and GilOII; Fre: E. coli 
flavin reductase. 
Under these conditions, a new peak (98) was observable at a wavelength of 420 
nm (Figure 3.2, trace A). After the reaction was run several times, ca. 90 μg of 98 were 
isolated for NMR characterization. The 1H NMR spectrum of the new compound showed 
a considerable upfield shift of H5, which also showed a coupling with a new proton 
signal at δ 3.56. The latter was exchangeable with D2O. The complete spectral 
characterization along with high-resolution mass spectrometry revealed 98 to possess a 
tetracyclic core with a unique hydroxy-oxepinone ring B (98, Scheme 3.3). The 
production of 98 clearly proved that GilOII is solely responsible for the key C–C bond 
cleavage. In the absence of FAD, NADPH or flavin reductase Fre, the assay failed to 
consume any starting material or to yield any product (Figure 3.2, trace B). 
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Figure 0.2 HPLC traces of the enzymatic reactions: A) dehydrorabelomycin (73) + GilOII + 
NADPH + FAD + Fre, B) 73 + GilOII C) 73 + GilOII + NADPH + Fre (traces of 98 were formed 
due to traces of FAD co-purified with Fre), D) 73 + JadG + GilMT + GilM + GilR producing 
defucogilvocarcin M (45), E) 73 + JadG + NADPH + FAD + Fre. 
This proved that co-factor FADH2 (here produced in situ from FAD and NADPH 
by Fre) is absolutely necessary, although the BLAST analysis showed that GilOII has no 
recognizable FAD-binding site. In fact, the enzyme resembles mostly co-factor free 
anthrone oxygenases, and we had considered that GilOII might act by a mechanism 
similar to that recently proposed for the cofactor-independent dioxygenase DpgC(93) 
involved in the biosynthesis of the dihydroxyphenylglyoxylate building block of 
glycoprotein antibiotics, as a possible alternative to the earlier proposed Baeyer-Villiger 
oxidation mechanism [Scheme 3.4, path B (in blue) vs path A (in green)]. The above 
described GilOII reaction and the isolated compound 98 were also critical for solving this 
mechanistic ambiguity. The stepwise mechanism, 5-hydroxylation followed by Baeyer-
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Villiger oxidation (Scheme 3.4, path A, green) was corroborated, while the dioxygenase 
mechanism involving a dioxetane intermediate (Scheme 3.4, path B, blue) could be 
refuted. The observation that the experiment without FAD also produced a small amount 
of the product 98 (Figure 3.2, trace C) was tracked to small quantities of FAD that were 
co-purified with Fre. The insufficient supply of FAD in the experiment monitored by 
trace C (Figure 3.2) also explained well the incomplete conversion of starting material 73 
to 98. 
Next we wanted to verify that compound 98 is a true intermediate of the pathway, 
and not a shunt product. We monitored conversion of 98 to defucogilvocarcin M (45) 
when it was incubated with a mixture of GilM, GilMT, and GilR. However, any 
combination of these three enzymes and suitable cofactors failed to convert 98 to 45. 
Only upon addition of GilOII was 98 converted to 45 (Figure 3.3). This clearly proves 
oxepinone 98 is a pathway intermediate of the gilvocarcin biosynthesis. When 98 was 
incubated with GilOII alone, it was completely consumed, but no product was 
accumulated. This could be attributed to the unstable nature of the expected aldehyde (84 
or its carboxylated analogue). Overall, GilOII not only mediates C-5 hydroxylation and 
the following Baeyer-Villiger oxidation, but is also critical for the ring opening. 
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Figure 0.3 (Top) In vitro reactions of 98 with different combinations of downstream enzymes; 
GilOII, GilM, GilMT and GilR. (Bottom) HPLC traces of the enzymatic reactions: A) 98 + 
GilMT + GilM + GilR + Fre + FAD + NADPH; B) 98 + GilOII; C) 98 + GilOII + GilMT + GilM 
+ GilR + Fre + FAD + NADPH. 
Investigating JadG 
Finally we wanted to investigate whether the closely related jadomycin 
biosynthesis also follows the same pathway regarding the C–C bond cleavage. It had 
recently been reported that dehydrorabelomycin (73) is also a biosynthetic intermediate 
of the jadomycin A pathway.(94, 95) Among the three oxygenases reported in the 
biosynthetic pathway of jadomycin, JadG (also a seemingly co-factor free anthrone 
oxygenase) showed the highest similarity with GilOII (51.5%). Thus, JadG was 
expressed in E. coli, purified to near-homogeneity, and incubated with a mixture of GilM, 
GilMT, GilR, and the substrate 73. All the substrate was converted into 45 (Figure 3.2, 
trace D), confirming our hypothesis. The results here demonstrate the functional 
equivalence of GilOII and JadG, although earlier cross-complementation experiments 
showed that swapping of gilOII with jadG in the gilOII-deleted mutant failed to restore 
gilvocarcin production.(69) Adding JadG to a mixture of NADPH, FAD, Fre, and 
dehydrorabelomycin (73) successfully produced hydroxyoxepinone 98 (Figure 3.2, trace 
E). Thus, the jadomycin biosynthesis shares the same C–C bond key cleavage reaction in 
its biosynthetic pathway as found for the gilvocarcin pathway.   
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Scheme 0.4 Mechanistic alternatives for the key C–C bond cleavage reaction. 
3.2. Discussion 
In conclusion, we have shown that two previously believed cofactor free 
oxygenases, GilOII and JadG, are indeed FADH2-depedent and are responsible for the 
critical C5–C6 bond cleavage of the benz[a]-anthracene skeleton of angucyclinone 
intermediate 73 and the subsequent rearrangements during the biosyntheses of 
gilvocarcin and jadomycin, respectively. These enzymes are not cofactor-independent, 
despite misleading BLAST search results indicating that these enzymes mostly resemble 
cofactor-free anthrone oxygenases, such as TcmH (43% aa-identity with GilOII)(31) or 
AknX (34% aa-identity with GilOII).(96) Anthrone oxygenases require a second 
oxidation (dehydrogenation) of the immediate hydroquinone to the corresponding 
quinone to produce the necessary two H atoms for the formation of the second product, a 
molecule of H2O. Although GilOII and JadG catalyze a similar first reaction, namely 
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formation of an ‘ortho-hydroquinone’, this is not further oxidized to an ortho-quinone, 
and requires FADH2 instead for the H2O-formation. Since the product FAD has to leave 
the active site to be re-reduced to FADH2 (in our experiment by Fre and in the gil-
pathway presumably by GilH), the cofactor has to move freely and cannot have a tight 
binding site. The reaction is sequential and requires 2 equiv of FADH2 since the enzymes 
catalyze both an initial 5-hydroxylation and the following Baeyer-Villiger oxidation, 
which initiates the scaffold rearrangements in these pathways. The work described here 
closes the gaps of the gilvocarcin and jadomycin biosyntheses, since oxepinone 98 opens 
under decarboxylation into aldehyde 84, which had been synthesized and proven to be an 
intermediate of both the gilvocarcin(92) and jadomycin(18) pathways. Baeyer-Villiger 
monooxygenases(97) were also suggested or proven to play key roles in the biosynthesis 
of other natural products, e.g., the pentalenolactones,(98) the aureolic acids,(30) 
BE7585A,(99) the aflatoxins,(100) and in addition play major roles in degradation 
processes such as the recently deciphered toxoflavin degradation.(101)     
3.3. Experimental 
Section A. Bacterial strains culture conditions and isolation of compounds 
Standard prejadomycin for the large scale preparation of dehydrorabelomycin 
(73) and defucogilvocarcin M (45) were isolated from the S. lividans TK24 (cosG9B3-
OI¯) and S. lividans TK24 (cosG9B3-GT¯) mutant respectively, following previously 
reported procedure.(69) The spores of cultured Streptomyces strains on apramycin sulfate 
(50 μg mL-1) supplemented M2 agar were inoculated into SG liquid medium (100 mL). 
The seed culture thus prepared was then taken for inoculation of production scale SG 
medium (5 L; 100 mL × 50 flasks) and grown for 7 days. The culture broth was separated 
from the mycelia through centrifugation (4000×g, 30 min) and the culture broth was 
extracted twice with equal volumes of ethyl acetate. The mycelia portion was extracted 
with acetone by sonication. Both the acetone and the ethyl acetate extract were dried 
together and the product was purified using preparative scale HPLC (monitored at 254 
nm). A linear gradient of acetonitrile and water (solvent A = H2O; solvent B = 
acetonitrile; 0–15 min 25% B to 100% B; 16–24 min 100% B; 25–26 min 100% to 25% 
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B; 27–29 min 25% B) with flow rate of 2.5 mL/min was used to separate the compounds 
in a Waters Symmetry Prep C18 7μm (19 × 150 mm) column. A photodiode array detector 
(Waters 2996) along with a Micromass ZQ 2000 mass spectrometer (Waters Corporation) 
equipped with an atmospheric pressure chemical ionization (APCI) probe was used for 
the identification of the compounds.  
Section B. List of primers used in this study 
Table 0.1 List of primers used in this study 
Name of the 
primers 
Oligonucleotide sequence (5′→3′) 
GilOII_for GGCCATATGCCGATCATCGAGCCCGAGAAC 
GilOII_rev CGGGAATTCTCACGACGCGTACCCCTCGACCGA 
JadG_for ATCATATGCCTCTGATCAACCCCGAAG 
JadG_rev ATGAATTCCTACTCCGCCGAGCGCGAGTG 
GilM_for CGCCATATGCCAACGGGCAGCACGGAGAAGATC 
GilM_rev CGGGAATTCTCATGCCGGGCTCTCCGATCGGGT 
GilMT_for GACCATATGACCATTACTGCATCGGGATCG 
GilMT_rev CGGGAATTCTCACCGGCTGCGGGGAGAGCCCGG 
 
Section C. Expression and purification of enzymes 
All of the genes were expressed with N-terminal polyhistidine tag using pET-28a-
expression constructs in E. coli BL21 (DE3). For the purpose of seed culture a single 
colony was selected and grown in LB liquid (20 mL) supplemented with kanamycin 
sulfate (50 μg mL-1) for 4 h. The seed was used to inoculate (10 mL/L) a large scale LB 
culture and grown at 37 °C until OD600 reached 0.5. The protein production was induced 
by the addition of isopropyl-β-D-1-thio-galactopyranoside (IPTG, 0.2 mM final 
concentration) and the culture was allowed to grow at 18 °C for 12 h. The cell pellets 
were collected by centrifugation and washed with lysis buffer (50 mM KH2PO4, 300 mM 
KCl, 10 mM imidazole, pH 8.0). A French Press (Thermo Electron Corporation) was 
used to disrupt the cells and the crude soluble N-terminal (His)6-tagged enzyme fractions 
were purified through metal talon affinity resin (BD Biosciences) using elution buffer (50 
mM KH2PO4, 300 mM KCl, 250 mM imidazole, pH 8.0). The size exclusion filters were 
used for final desalting. The protein concentrations were determined by the Bradford 
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method using a calibration curve of the known concentrations of BSA and the purities 
were estimated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analyses.(102) The measured sizes of the proteins were in good agreement with 
the calculated one. For storage purpose of the purified enzymes 50 mM phosphate buffer 
(pH 7.5) supplemented with glycerol (25% final volume) were used.  
Section D. Combinatorial biosynthetic enzymology experiments 
Enzymatic reactions carried out using dehydrorabelomycin (73) as substrate along 
with different combinations of enzymes are described below. All the reactions for the 
combinatorial studies contained phosphate buffer (pH 6.5, 50 mM), dehydrorabelomycin 
(50 μM), NADPH (50 μM), FAD (50 μM), SAM (100 μM), E. coli Fre (2 μM), and an 
NADPH regeneration system consisting of glucose-6-phosphate (10 mM) and glucose-6-
phosphate dehydrogenase (10 μM). 1 mL assay mixture was incubated with different 
combinations of enzymes (10–15 μM of each) for 6–8 h and the reactions were monitored 
using the HPLC conditions described in section A at 375 nm.  
Table 0.2 In vitro enzymatic reactions of 73.      
Expt. No. GilOII/JadG GilM GilMT GilR Product(s) 
1 + + + + defucogilvocarcin M (45) 
2 + + + - defucopregilvocarcin M (52) 
3 + + - - Starting material decomposed 
 
Section E. In vitro enzymatic reactions 
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Synthesis of dehydrorabelomycin (73) from prejadomycin 
An assay mixture (10 mL) containing phosphate buffer (pH 6.5, 50 mM), 
prejadomycin (80 μM), GilOI (15 μM), NADPH (20 μM), glucose-6-phosphate (2 mM), 
and glucose-6-phosphate dehydrogenase (10 μM) was incubated at 28 °C for 6 h. The 
reaction was extracted with ethyl acetate (3 × 20 mL), concentrated under reduced 
pressure and purified using preparative scale HPLC following the conditions mentioned 
in section A (monitored at 460 nm). The product dehydrorabelomycin (73) was obtained 
almost in quantitative amounts.(78) 
Reaction of dehydrorabelomycin (73) with GilMT 
An assay mixture (5 mL) containing phosphate buffer (pH 6.5, 50 mM), 
dehydrorabelomycin (73) (60 μM), GilMT (120 μM), and S-adenosylmethionine chloride 
(SAM) (200 μM) was incubated at 28 °C for 4 hours. The reaction was stopped by flash-
cooling to -78 ºC (dry ice/acetone bath) and the product was extracted with ethyl acetate 
(3 × 10 mL). The organic layer was dried under reduced pressure and purified using 
HPLC following the conditions mentioned in section A (monitored at 460 nm). The yield 
of the product 95 was ~ 90% while both of the 96 and 97 was produced < 1%. 
Table 0.3 High resolution mass spectroscopy data of compounds 95–97. 
Compound HRMS (+EI) 
Calc’d Observed 
95; C21H16O5 348.0998 348.0999 
96; C20H14O5 334.0841 334.0850 
97; C20H14O5 334.0841 334.0847 
 
Reaction of dehydrorabelomycin (73) with GilOII to produce compound 98 
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A typical assay mixture (1 mL) containing phosphate buffer (pH 6.5, 50 mM), 
dehydrorabelomycin (73) (50 μM), GilOII (12 μM), glucose-6-phosphate (1 mM), 
glucose-6-phosphate dehydrogenase (10 μM), FAD (50 μM), NADPH (20 μM), and E. 
coli Fre (2 μM) was incubated at 28 °C for 8 hours. The reaction was stopped by flash-
cooling to -78 ºC (dry ice/acetone bath) and the product was extracted with ethyl acetate 
(3 × 2 mL). The organic layer was dried under reduced pressure and purified using HPLC 
following the conditions mentioned in section A (monitored at 420 nm). This reaction 
was repeated ~ 200 times to yield a combined product 98 of ~ 90 μg. HRMS (ESI): [M - 
H2O]+ Calc’d for C19H12O7 : 335.0555, observed: 335.0555. 
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Section F. Spectral data 
The NMR spectra were acquired on a Varian MR 400 spectrometer (B0 9.4 T) and 
a Bruker Avance 600 (B0 14.09 T) spectrometer equipped with a 1.7 mm cryoprobe and a 
Bruker Avance 500 (B0 11.74 T) spectrometer equipped with a 5 mm cryoprobe. 
Deuterated chloroform was used as NMR solvent for all spectra recorded.  
 
1,8-Dimethoxy dehydrorabelomycin (95) 
Table 0.4 1H, 13C , NOESY and gHMBC data for 1,8-Dimethoxy dehydrorabelomycin (95) in 
CDCl3 (500 MHz, relative to internal TMS, J in Hz). 
Position 1H NMR 13C 
NMR 
1D NOESY gHMBC 
1 - 157.1 - - 
1-OMe 3.92 (s, 3H) 56.1 - 1 
1a - 115.8 -  
2 6.64 (s, 1H) 108.6 1-OMe, 3-Me 4, 3-Me 
3 - 141.6 - - 
3-Me 2.47 (s, 3H) 22.5 - 2, 3, 4 
4 7.06 (s, 1H) 118.6 3-Me, 5-H 1a, 2, 5 
4a - 137.0 - - 
5 7.34 (s, 1H) 117.1 4-H 1a, 4, 6, 12a 
6 - 157.1 - - 
6-OH 12.25 (s, 1H) - - 5, 6, 12a 
7 - 188.9 - - 
7a - 140.4 - - 
8 - 160.1 - - 
8a - 120.2 - - 
8-OMe 4.06 (s, 3H) 56.8 - 8 
9 7.27 (d, 1H, J = 8.0 Hz) 116.8 8-OMe, 10-H 8a, 11 
10 7.72 (dd, 1H, J = 8.0, 7.5 
Hz) 
136.2 - 8, 11a 
11 7.66 (d, 1H, J = 7.5 Hz) 118.8 - 8a, 9, 12 
11a - 139.4 - - 
12 - 186.7 - - 
12a - 119.7 - - 
 
70 
 
 
1-Methoxy dehydrorabelomycin (96)                        8-Methoxy dehydrorabelomycin (97) 
Table 0.5 1H data for 96 and 97 in CDCl3 (500 MHz, relative to internal TMS, J in Hz). 
Position 1H NMR of 96 1H NMR of 97 
1 - - 
1-OMe/1-OH 3.92  (s, 3H)  10.12 (s, 1H) 
1a - - 
2 6.65 (s, 1H) 6.94 (s, 1H) 
3 - - 
3-Me 2.48 (s, 3H) 2.44 (s, 3H) 
4 7.07 (s, 1H) 7.09 (s, 1H) 
4a - - 
5 7.36 (s, 1H) 7.65 (s, 1H) 
6 - - 
6-OH 11.67 (s, 1H) 12.72 (s, 1H) 
7 - - 
7a - - 
8 - - 
8a - - 
8-OH/8-OMe 11.58 (s, 1H) 4.09 (s, 3H)  
9 7.38 (d, 1H, J = 9.0 Hz) 7.27 (d, 1H, J = 8.5 Hz) 
10 7.72 (dd, 1H, J = 8.0, 7.5 Hz) 7.78 (dd, 1H, J = 8.0, 8.5 
Hz) 
11 7.58 (dd, 1H, J = 7.5, 1.5 Hz) 7.91 (dd, 1H, J = 7.5, 1.0 
Hz) 
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Oxepinone derivative 98 
Table 0.6 1H, 13C , gHSQC and gHMBC data for 98 in CDCl3  
Position 1H NMR 13C NMR HSQC HMBC 
1 - 155.1 -  
1-OH 10.89 (s) -  1a, 1, 2 
1a - 108.2*   
2 6.96 (s) 122.0 122.0 1a, 4 
3 - not observed   
3-Me 2.38 (s) 21.4 21.4 2, 4, 4a 
4 6.74 (s) 119.1 119.1 1a, 2, 3-CH3, 5 
4a - 143.7*   
5 6.52 (d, J = 5.5 Hz) 94.5 94.5  
5-OH 3.56 (d, J = 5.5 Hz)  D2O exchangeable 
-   
6 - not observed   
7 - 183.7   
7a - 144.2   
8 - 161.8   
8-OH 11.72 (s) -  8a, 8, 9 
8a -   113.5*   
9 7.31 (d, J = 8.5 Hz) 125.4 125.4 8a 
10 7.67 (dd, J = 8.5, 7.5 Hz) 137.3 
137.3  
11 7.83 (d, J = 7.5 Hz) 121.5 121.5 8a, 9,12 
11a - 132.4   
12 -  186.7*   
12a - 140.9   
* From HMBC 
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Chapter 4. Exploring promiscuous GilM and GilMT: Chemoenzymatic synthesis of 
pre-defucogilvocarcin M analogues 
Constructing gilvocarcin’s core is a difficult synthetic venture. In the past two 
decades several synthetic groups tried and demonstrated a long streak of steps required to 
generate the core.(103-106) Recently, Snieckus and James reported a 20 step long total 
synthesis of defucogilvocarcin M (45).(104) Despite several attempts, none of the 
synthetic groups succeeded in providing protocols that are short and practical. Synthetic 
chemistry has long been used to generate natural products and their structural analogues. 
Additionally, chemical synthesis offers great opportunities to provide pharmacologically 
improved molecules. Unfortunatly, these syntheses occasionally become challenging to 
scale up because of structural complexities within these molecules. In such cases, it 
becomes imperative to develop new strategies that can overcome synthetic hurdles.  
The catalytic power of the enzymes from biosynthetic pathways could be 
harnessed and used to aid traditional synthetic protocols in the efficient and economical 
generation of natural product analogues.(107-111) A deep understanding of the gene 
products involved in the biosynthetic manufacturing of gilvocarcin has enabled us to 
exploit various downstream enzymes in the achievement of difficult synthetic steps 
(Scheme 4.1). In this section, we report our initial attempts to explore the proposed 
chemoenzymatic synthesis, where two critical downstream enzymes, GilM and GilMT, 
were investigated with respect to their substrate flexibility. A small series of analogues of 
compound 84 generated via chemical route were fed to various mixtures of the enzymes 
and the reactions were analyzed to establish the diversity of substrates tolerated. 
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Scheme 0.1 Chemoenzymatic strategy for the synthesis of pre-defucoGM analogues.  
4.1. Results and Discussions 
Our strategy capitalized on the easy and practical synthesis of compound 84 as 
discussed in chapter 2. We used the synthetic route to compound 84, utilizing Stille 
coupling, as a framework for generating analogues. Our initial attempts focused on 
varying the position of hydroxyl group on ring A. With this idea in mind, we attempted 
controled introduction of bromine into the 3-position of the commercially available 
juglone (Scheme 4.2).(112, 113) The treatment with bromine was followed by 
debromination of the crude dibrominated adduct selectively gave 3-bromojuglone (99) as 
an orange solid. The differences in melting point and the polarities of the 2- and 3-
regioisomers assisted in an easy separation of the two. A palladium catalyzed Stille 
coupling reaction between 86 and 99 yielded the coupled product in 75% yield. A careful 
acidic treatment with concentrated HCl in acetonitrile provided the desired product, 
containing a hydroxyl group at position-8, as an orange solid. 
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Scheme 0.2 Synthesis of 100. 
We also considered analogues with additional hydroxyl groups as suitable 
substrates for GilM and GilMT. We envisaged that an additional hydroxyl or amino 
group should add more polar properties into the molecule, rendering it more water-
soluble. The compound 101 with an additional hydroxyl group in 10-position was 
proposed to be assembled by a Stille coupling between dihydroxy-bromojuglone (102) 
and 86 (Scheme 4.3).  102 was prepared by a Diels–Alder addition of 1-methoxy-1,3-
bis(trimethylsilyloxy)-1,3-butadiene (105) to 2,5-dibromo-1,4-benzoquinone (107) in dry 
benzene (Scheme 4.3).(114) The latter was synthesized via ceric ammonium nitrate 
(CAN)-mediated oxidative demethylation of 2,5-dibromo-1,4-dimethoxybenzene.(115) 
The diene 105 was prepared from silyl enol ether 104 (Scheme 4.4) that in turn was 
accessible from methyl acetoacetate following a procedure reported in literature.(116) A 
solution of freshly distilled methyl acetoacetate and triethylamine in hexane was treated 
with trimethylsilyl chloride and stirred for 18 h. The resulting mixture was passed 
through celite and the filtrate was concentrated and distilled (100 °C/20 mmHg) to give 
methyl-3-(trimethylsiloxy)-2-butenoate (104). Methyl-3-(trimethylsiloxy)-2-butenoate 
was deprotonated with freshly prepared LDA in THF at -78 °C followed by silylation 
with trimethylsilylchloride to give the desired diene in 95% yield. A palladium catalyzed 
coupling between 102 and 86 yielded the protected coupled product (108) in 4% yield. 
The routine treatment of the protected compound 108 with 2.4 M HCl in acetonitrile 
resulted in decomposition of the material. We tried acidifying the reaction mixture at low 
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temperatures but that was also unsuccesful. Unfortunately, several attempts to deprotect 
the MOM group failed to yield the desired product (101). 
 
Scheme 0.3 Retrosynthetic analysis of 101. 
 
Scheme 0.4 Attempted synthesis of 101. 
We then moved our focus to the substituted hydroxyl derivative (112). The 
formation of 2-chloro-6-methoxy-8-hydroxy-1,4-naphthoquinone (111) was achieved 
through a Diels-Alder cycloaddition of the Bassard’s diene (109)(117) onto the  
commercially available 2,6-dichloro-1,4-benzoquinone (110). This reaction was 
perfomed at -30 °C in THF followed by a vigorous aromatization for  24 h at room 
temperature in presence of excess deactivated silica (Scheme 4.5).(118) The resulting 
napthoquinone (111) was coupled with stannane 86 and subsequently subjected toacidic 
deprotection. A room temperature acid treatment resulted in decomposition of the starting 
material with no product formation. However, a very careful HCl treatment at 0°C 
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provided the desired analogue in very low yields (2%). Acidification at even lower 
temperatures did not affect the yield.  
 
Scheme 0.5 Synthesis of 112. 
Another venture was to see whether the enzymes can handle more bulky 
substrate, i.e. to see how strict GilM was with respect to sterical requirements. Thus, a 
benzylated substrate was well suited for the study. Benzylation of bromojuglone (85) was 
carried out with freshly prepared silver oxide and benzyl chloride. Palladium catalyzed 
coupling with 86 followed by global acidic deprotection provided the benzylated 
substrate (114) (Scheme 4.6). 
 
Scheme 0.6 Synthesis of benzylated derivative 114. 
We also sought to check if the hydroxyl group in 5’-position in the natural 
substrate (84) and methyl group in 5-position were critical for enzyme activity.  Coupling 
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between commercially available 2-bromo-1,4-naphthoquinone (115) and the stannane 86 
followed by acidic deprotected yielded the required fully deprotected analogue (116). 
 
Scheme 0.7 Synthesis of 116. 
The demethylated analogue (120) was prepared by coupling bromo-juglone (85) 
and stannane (119) (Scheme 4.8). Synthesis of the latter began from commercially 
available m-hydroxybenzaldehyde (117). Protection of the hydroxyl group as a MOM 
ether and the aldehyde as a cyclic acetal group provided substrate (118) for ortho-
lithiation. n-Butyl lithium-mediated selective ortho-deprotonation followed by quenching 
with tributyltinchloride gave the required stannane (119) in 88% yield. A low-
temperature acidic treatment of the coupled product provided analogue 120 along with 
small quantities of the MOM-protected derivative 121, which we thought was a great 
analogue to test if the enzymes could tolerate ethers other than methyl ether  (92). 
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Scheme 0.8 Synthesis of derivatives 120 and 121. 
After developing a small series of analogues with different substituents decorating 
the core substrate, we fed them to a mixture of GilM and GilMT and analyzed the 
reactions at different time points. An assay mixture (0.5 mL) composed of phosphate 
buffer (pH 6.5, 50 mM), substrate analogue (10 μM), S-adenosylmethionine (excess), 
GilMT (1 μM), and GilM (1 μM) was incubated at 30 °C. 100 μl of assay mixture was 
withdrawn at progressive time intervals of time and was extracted with EtOAc (2 × 250 
μL). The organic solvent was dried at low pressure and the crude product was dissolved 
in CH3CN. The solution was then subjected to LC-MS analysis. A linear gradient of 
acetonitrile and 0.1% formic acid-water (solvent A = 0.1% formic acid-H2O; solvent B = 
acetonitrile; 0-15 min 25% B to 100% B; 16-24 min 100% B; 25-26 min 100% to 25% B; 
27-29 min 25% B) with flow rate of 0.5 mL/min was used to separate the compounds in a 
Waters Symmetry C18 (4.6 × 250 mm, 5μm) column. 
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Figure 0.1 HPLC traces of the enzymatic reactions with 100: (A) standard 100; (B) 100 + GilM + 
GilMT + SAM + 15 min; (C) 100 + GilM + GilMT + SAM + 2 h; (D) 100 + GilM + GilMT + 
SAM + 18 h. 
Figure 4.1 shows the HPLC traces of the enzymatic reactions of analogue 100 
with GilM and GilMT in presence of SAM. Compound 100 underwent initial quinone 
reduction to generate the hydroquinone, followed by subsequent intramolecular 
cyclization to give hemiacetal 122 (Figure 4.1, trace B). GilM, as expected, catalyzed the 
first O-methylation followed by a GilMT-mediated second O-methylation to give the 
anticipated defuco-pregilvocarcin M analogue 123 (Figure 4.1, trace C). Further 
incubation of the enzyme mixture for 18 h resulted in over methylated product 124 
(Figure 4.1, trace D). The ability of GilM and GilMT to catalyze the series of the 
reactions leading from 100 to 123, shows that both GilM and GilMT are broad enough to 
accommodate other regioisomers with respect to the hydroxyl group in ring A.  
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Figure 0.2 HPLC traces of the enzymatic reactions with 112: (A) standard 112; (B) 112 + GilM + 
GilMT + SAM + 18 h. 
When compound 112, with an additional methoxy group in 6’-position, was 
incubated with GilM and GilMT, no new product was produced after the first 4 h. 
However, after overnight incubation, a new peak was formed with a longer retention time 
in comparison to the starting material and a chromophore similar to that of defuco-
pregilvocarcin M. Low-resolution mass analysis of the new peak is consistent with 
compound structure 125 (Figure 4.2; trace B). Based on the area under curve of the 
HPLC peak the conversion was 15%.  The very slow turnover of 112 by GilM shows that 
GilM’s binding pocket can hardly accommodate an additional methoxy group in 6’-
position. To further test GilM’s ability to handle bulky substrates, we incubated the 
benzylated derivative 114 with GilM and GilMT. This reaction did not accumulate any 
cyclized product clearly indicating that the GilM catalytic pocket has enough extra room 
to accommodate smaller substituents but is too tight for bulky substituents like benzyl 
groups. 
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Figure 0.3 HPLC traces of the enzymatic reactions with 116: (A) standard 116; (B) 116 + GilM + 
GilMT + SAM + 2 h. 
To further explore the sterical effects and interrogate whether the hydroxyl group 
in 5’-position and methyl group in 5-position of compound 84 are critical for enzyme 
activities, we incubated demethylated derivative 116 with GilM and GilMT. As 
anticipated, after 2 h 116 was fully converted to 126 (Figure 4.3; trace B). Compound 116 
is of particular interest as it would be useful in solving the often-asked question of 
whether or not the 1-OH of predefuco-gilvocarcin M (52) directs the glycosylation 
reaction in 4-position. The demethylated derivative 120 was also tested and found to be 
successfully turned over by a mixture of GilM and GilMT (Figure 4.4). 
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Figure 0.4 HPLC traces of the enzymatic reactions with 120: (A) standard 120; (B) 120 + GilM + 
GilMT + SAM + 15 min; (C) 120 + GilM + GilMT + SAM + 2 h; (D) 120 + GilM + GilMT + 
SAM + 18 h. 
Furthermore, compound 121 with its 3-OH presubstituted with the bulkier 
methoxy methyl ether, was additionally found to be smoothly accepted as a substrate by 
both GilM and GilMT (Figure 4.5). After incubation with GilM for 15 min, 121 
underwent quinone reduction and cyclization to form the hemiacetal, a demethyl-
predefucogilvocarcin 130 type derivative (Figure 4.5; trace B). After an 18 h incubation 
period, compound 132 was isolated (Figure 4.5; trace D). Strikingly, GilM is 
promiscuous enough to accommodate a wide variety of substrates. The enzymatic 
conversion of 121 to 132 is a major stepping-stone towards total chemoenzymatic 
synthesis of gilvocarcin type compounds with diverse range of pharmacophores.  
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Figure 0.5 HPLC traces of the enzymatic reactions with 121: (A) standard 121; (B) 121 + GilM + 
GilMT + SAM + 15 min; (C) 121 + GilM + GilMT + SAM + 2 h; (D) 121 + GilM + GilMT + 
SAM + 18 h. 
All analogues, except the bulky benzylated derivative 114, showed a sequence of 
events similar to those displayed by the natural substrate 84. GilM was shown to be 
relatively accommodating towards aromatic substitution patterns different from the 
natural substrate. Additonally, GilMT was shown to be more promiscuous than GilM. 
Interesting, it was also found that when the reaction mixtures were left for 18 h or more 
GilMT catalyzed a second O-methylation despite occupation of the first catalytic site. 
This initial testing of substrates for GilM and GilMT and chemoenzymatic synthesis of 
defuco-preGM type analogues forges the way for future exploration of more drastic 
substrates. From the drug development standpoint, our findings make the future 
prospectives of a gilovocarcin type anticancer antibiotic look even brighter then 
previously thought. 
4.2. Experimental 
3-bromojuglone (99)  
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A suspension of commercially available juglone (1.2 g, 6.89 mmol) in acetic acid (18 
mL) was treated with bromine (6.89 mmol, 0.36 mL) in the dark at 25 °C. After stirring 
for 15 min, the reaction mixture was poured onto ice and the resulting slurry stirred. After 
10 min the dibrominated intermediate was filtered off under reduced pressure. The 
resulting solid was washed with 5 mL of ice-water followed by immediate washing with 
ethanol (10 mL) and stirring for 10 min under reflux. The mixture was cooled down to 
room temperature and the resulting red precipitate was filtered off under reduced 
pressure. After washing with cold ethanol, the residue was subjected to silica gel 
chromatography to give 3-bromojuglone 99(113) as an orange solid (1.4 g, 80%). M.p. 
170 °C; 1H NMR (500 MHz, CDCl3) δ 11.7 (s, 1H), 7.66–7.61 (m, 2H), 7.47 (s, 1H), 
7.29 (dd, J = 8 Hz, 1.5 Hz, 1H). 
Compound 100 
 
A suspension of 3-bromo-5-hydroxy-1,4-naphthaquinone 99 (48 mg, 0.19 mmol), 
stannane 86 (100 mg, 0.19 mmol), and CuI (3.8 mg, 0.02 mmol) in THF (4 mL) was 
added to a solution of Pd2(dba)3•CHCl3 (4.9 mg, 0.0045 mmol) and PPh3 (5.4 mg, 0.02 
mmol) in THF (1 mL). The mixture was heated at 75 °C for 12 h. The mixture was 
cooled to 0°C and diluted with EtOAc (10 mL). Saturated aqueous NaHCO3 (10 mL) was 
added and the mixture was stirred for 30 min. The layers were separated and the aqueous 
layer extracted twice with EtOAc (25 mL). The combined organic layers were washed 
with brine and dried over Na2SO4. The solvent was removed under vacuum and the 
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resulting residue subjected to flash silica gel column chromatography to provide the 
coupled product (20% EtOAc-hexane, Rf = 0.25) as an orange solid (75%). 1H NMR 
(acetone-d6, 500 MHz) δ 12.0 (s, 1H), 7.80 (dd, J = 8.5, 7.5 Hz, 1H), 7.65 (dd, J = 7.5, 1.0 
Hz, 1H), 7.35 (dd, J = 8.5, 1 Hz, 1H), 7.16 (d, J = 0.5 Hz, 1H), 7.07 (d, J = 0.5 Hz, 1H), 
6.89 (s, 1H), 5.50 (s, 1H), 5.13 (s, 2H), 4.03–3.96 (m, 2H), 3.86–3.75 (m, 2H), 3.33 (s, 
3H), 2.39 (s, 3H), 1.98–1.85 (m, 1H); 13C NMR (acetone-d6, 125 MHz) δ 190.5, 184.6, 
162.4, 155.4, 148.2, 140.8, 139.2, 138.9, 137.5, 124.7, 121.3, 119.1, 115.8, 100.7, 95.3, 
67.6, 56.3, 26.4, 23.3, 21.8, 14.4. (+EI): Calc’d for C23H22O7 410.1365, observed: 
410.1362. 
A solution of concentrated HCl (2 mL) in 10 mL CH3CN was added to the above coupled 
product (55 mg, 0.13 mmol) in a 250 mL flask at r.t. The mixture was stirred for 4 min, 
quenched with NaHCO3 (60 mL), and EtOAc (50 mL) was added. After separation of the 
layers, the aqueous layer was extracted with EtOAc twice. The combined organic layer 
was washed with brine, dried over Na2SO4. The solvent was then removed under vacuum. 
The resulting residue was subjected to purification by flash silica gel column 
chromatography (40% EtOAc-hexane, Rf = 0.25)  to provide the desired product 100 as 
an orange solid (72%). 1H NMR (acetone-d6, 400 MHz) δ 11.93 (bs, 1H), 9.94 (s, 1H), 
9.02 (bs, 1H), 7.83 (t, J = 10.5 Hz, 1H), 7.66–7.64 (m, 1H), 7.41–7.34 (m, 2H), 7.20–7.18 
(m, 1H), 6.95 (s, 1H), 2.39 (s, 3H); 13C NMR (acetone-d6, 100 MHz) δ 193.0, 190.5, 
184.5, 162.5, 156.1, 147.5, 142.1, 138.7, 137.7, 137.3, 133.6, 126.4, 124.8, 124.7, 123.3, 
119.2, 116.4,  21.1; HRMS (+EI): Calc’d for C18H12O5: 308.0685, observed: 308.0686. 
1,3-Bis(trimethylsiloxy)-1-methoxybuta-1,3-diene (105) 
 
Trimethylsilyl chloride (1.3 mL, 9.2 mmol) in dropwise increments was added to a 
solution of freshly distilled methyl acetoacetate (1.0 mL, 9.2 mmol) and triethylamine 
(1.5 mL, 11.1 mmol) in hexane (10 mL). The resulting mixture was stirred at room 
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temperature for 18 h. The mixture was then passed through a short pad of celite and the 
filtrate concentrated in vacuo. The residue was distilled (100 °C/20 mmHg) to give 
methyl 3-(trimethylsiloxy)-2-butenoate (104) (80%). 104 (0.75g, 3.7 mmol) was added 
dropwise to a freshly prepared solution of LDA (4 mmol) in THF at –78 °C. After 30 min 
trimethylsilyl chloride (0.6 mL, 5 mmol) was slowly added and the reaction mixture 
warmed to 0 °C. After 1 h, all volatile materials were removed in vacuo at room 
temperature, and the residue washed with dry hexane. The residue was further distilled 
(50 °C/0.01 mmHg) to give 105 (97%).(116) 
2,5-Dibromo-1,4-benzoquinone (107) 
  
At room temperature, Br2 (4 mL, 72.5 mmol) in acetic acid (5 mL) was added dropwise 
to a solution of 1,4-dimethoxybenzene (106, 5g, 36.25 mmol) in acetic acid (10 mL). 
After stirring for 2 h, the solution was cooled and the resulting white precipitate of 2,5-
dibromo-1,4-dimethoxybenzene filtered. The filtrate was further diluted with water (15 
mL) and extracted with CHCl3 (2 X 10 mL). The organic layer was washed with 10% 
aqueous NaHCO3, dried over Na2SO4 and dried under vacuum to yielding a total amount 
of 10 g of 2,5-dibromo-1,4-dimethoxybenzene. A portion of the white solid (5 g, 16.9 
mmol) was dissolved in CH3CN (50 mL) in an oil bath at 100 °C. A solution of cerium 
ammonium nitrate (25.0 g, 45.6 mmol) in water (150mL) was added to the boiling 
CH3CN solution. After completion of the addition, the heat was turned off and the 
reacting mixture was left to cool to room temperature. The precipitate formed on cooling 
was filtered and washed with water (30 mL), yielding 3.8 g (80% overall) of 107, as a 
yellow solid.(115) HRMS (+EI): Calc’d for C6H2Br2O2: 263.8422, observed: 263.8416. 
2-Bromo-5,7-dihydroxy-1,4-naphthoquinone (102) 
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At room temperature and under nitrogen, a solution of diene 105 (1.0 g, 4 mmol) in dry 
benzene (10 mL) was added dropwise to a solution of 107 (0.94 g, 3.5 mmol) in dry 
benzene (10 mL). After stirring the reaction mixture overnight, the solvent was removed 
in vacuo to yield a crude residue. The residue was purified by flash chromatography (10% 
ethyl acetate–hexane; Rf = 0.25), followed by washing with methylene chloride to afford 
the adduct 102 (0.25 g, 25%) as a bright orange solid, mp 193.8 °C.(114) 1H NMR 
(acetone-d6, 500 MHz) δ 11.93 (bs, 1H), 10.5 (bs, 1H), 7.51 (s, 1H), 7.11 (d, J = 2.0 Hz, 
1H), 6.62 (d, J = 2.5 Hz, 1H); 13C NMR (acetone-d6, 125 MHz) δ 186.7, 177.9, 165.8, 
165.3, 141.7, 141.6, 139.7, 133.7, 110.8, 109.6, 108.8. 
Compound 108 
 
 A solution of 2-Bromo-5,7-dihydroxy-1,4-naphthoquinone 102 (50 mg, 0.18 mmol), 
stannane 86 (115 mg, 0.18 mmol), and CuI (3.8 mg, 0.02 mmol) in THF (4 mL) was 
added to a solution of Pd2(dba)3•CHCl3 (5.0 mg, 0.0045 mmol) and PPh3 (5.4 mg, 0.02 
mmol) in THF (1 mL). The mixture was heated at 75 °C for 12 h, cooled to 0 °C, and 
diluted with EtOAc (10 mL). Saturated aqueous NaHCO3 (10 mL) was added and the 
mixture was stirred for 30 min. The layers were separated and the aqueous layer was 
extracted twice with EtOAc (25 mL). The combined organic layers were washed with 
brine and dried over Na2SO4. The solvent was removed under vacuum and the resulting 
residue was subjected to flash silica gel column chromatography to provide the coupled 
product (25% EtOAc-hexane, Rf = 0.2) as orange solid (4%). 1H NMR (acetone-d6, 400 
MHz) δ 12.25 (bs, 1H), 7.13 (bs, 1H), 7.08 (d, J = 3.0 Hz, 1H), 7.02 (bs, 1H), 6.80 (s, 
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1H), 6.65 (bs, J = 3.0 Hz, 1H), 5.44 (s, 1H), 5.08 (s, 2H), 4.03–3.97 (m, 2H), 3.87–3.75 
(m, 2H), 3.31 (s, 3H), 2.37 (s, 3H), 1.99–1.90 (m, 2H); 13C NMR (acetone-d6, 100 MHz) 
δ 189.4, 183.2, 165.7, 165.1, 155.4, 148.9, 140.6, 139.1, 135.4, 132.8, 129.6, 121.2, 
115.9, 110.1, 109.1, 108.1, 100.7, 95.3, 67.7, 67.5, 56.3, 26.4, 21.7. 
Compound 111 
 
A solution of (1,3-dimethoxy-buta-1,3-dienyloxy)trimethylsilane(117) (3.4 g, 16.9 mmol) 
in dry THF (16 mL) was added dropwise at -30 °C to a solution of commercially 
available 2,6-dichloro-1,4- benzoquinone (1.0 g, 5.6 mmol) in dry THF (26 mL) followed 
by the addition of excess deactivated silica. The reaction was stirred for 24 h and warmed 
to room temperature. The mixture was passed through a short pad of celite and the filtrate 
was concentrated in vacuo. The resulting residue was subjected to flash silica gel column 
chromatography (10% ethyl acetate–hexane; Rf = 0.40) to provide the desired adduct in 
50% yield as an orange solid.(118) 1H NMR (CDCl3, 400 MHz) δ 11.89 (s, 1H), 7.16 (d, 
J = 3 Hz, 1H), 7.10 (s, 1H), 6.46 (d, J = 2 Hz, 1H), 3.89 (s, 3H); 13C NMR (CDCl3, 100 
MHz) δ 182.0, 181.0, 166.9, 165.2, 146.8, 136.2, 133.5, 109.1, 109.0, 106.3, 56.4. 
Compound 112 
 
To a solution of 111 (60 mg, 0.25 mmol), stannane 86 (130 mg, 0.25 mmol), and CuI (5.0 
mg, 0.026 mmol) in THF (4 mL) was added a solution of Pd2(dba)3•CHCl3 (6.4 mg, 
0.006 mmol) and PPh3 (6.9 mg, 0.026 mmol) in THF (1 mL). The mixture was heated at 
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75 °C for 12 h. The mixture was cooled to 0 °C and diluted with EtOAc (10 mL). 
Saturated aqueous NaHCO3 (10 mL) was added and the mixture was stirred for 30 min. 
The layers were separated and the aqueous layer was extracted twice with EtOAc (25 
mL). The combined organic layers were washed with brine and dried over Na2SO4. The 
solvent was removed under vacuum and the resulting residue was subjected to flash silica 
gel column chromatography to provide the coupled product (20% EtOAc-hexane, Rf = 
0.25) as orange solid (55%). 1H NMR (CDCl3, 400 MHz) δ 12.33 (s, 1H), 7.22 (d, J = 
2.4 Hz, 1H), 7.15 (bs, 1H), 6.99 (bs, 1H), 6.84 (s, 1H), 6.67 (d, J = 2 Hz, 1H), 5.31 (s, 
1H), 5.08 (dd, J = 18 Hz, 7.2 Hz, 2H), 4.09 (dd, J = 11.6 Hz, 4 Hz, 2H), 3.90 (s, 3H), 
3.78–3.68 (m, 2H), 3.34 (s, 3H), 2.37 (s, 3H), 2.07–1.97 (m, 2H); 13C NMR (CDCl3, 100 
MHz) δ 187.5, 184.6, 166.1, 164.6, 154.6, 148.1, 141.0, 137.7, 137.6, 134.1, 120.7, 
119.1, 115.6, 109.9, 107.2, 106.5, 100.4, 94.7, 67.4, 56.3, 25.6, 21.9. (+EI): Calc’d for 
C24H24O8 440.1471, observed: 440.1482. 
A solution of concentrated HCl (2 mL) in 10 mL CH3CN was added to the above coupled 
product (30 mg, 0.07 mmol) in a 250 mL flask at 0 °C. The mixture was stirred for 4 min 
and then was quenched with NaHCO3 (60 mL) followed by addition of EtOAc (50 mL). 
After separation of the layers, the aqueous layer was extracted twice with EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4 and the solvent was 
removed under vacuum. The resulting residue was subjected to purification by flash silica 
gel column chromatography (25% EtOAc-hexane, Rf = 0.20) to provide the desired 
product 112 as an orange-red solid (~2%). 1H NMR (acetone-d6, 400 MHz) δ 12.21 (s, 
1H), 9.93 (s, 1H), 8.97 (bs, 1H), 7.39 (d, J = 0.8 Hz, 1H), 7.18–7.15 (m, 2H), 6.89 (s, 
1H), 6.80 (d, J = 2.4 Hz, 1H), 5.63 (s, 1H), 4.00 (s, 3H), 2.43 (s, 3H); 13C NMR (acetone-
d6, 100 MHz) δ 191.9, 187.7, 183.4, 166.2, 155.1, 146.9, 141.0, 137.2, 136.4, 134.1, 
125.1, 122.2, 106.7, 105.6, 55.8, 20.1; (+EI): Calc’d for C19H14O6 338.0790, observed: 
338.0798. 
Compound 113 
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BnBr (0.75 mL, 6.25 mmol) at room temperature was added to a solution of 85 (0.8 g, 
3.12 mmol) in CH2Cl2 (10 mL), followed by the addition of freshly prepared Ag2O (1.4 
g, 6.2 mmol). The suspension was stirred at r. t. for 18 h, then filtered and rinsed with 
EtOAc. The filterate was concentrated under reduced pressure to give a residue which 
was subjected to silica gel column chromatography (20% EtOAc-hexane, Rf = 0.45) to 
give the desired product 113(83) as a yellow solid (1.0 g, 93%).1H NMR (CDCl3, 500 
MHz): δ 7.83 (dd, J = 8.0, 1.0 Hz, 1H); 7.65 (dd, J = 8.5, 8.0 Hz, 1H), 7.63 (dd, J = 7.0, 
0.5 Hz, 2H), 7.43–7.40 (m, 3H), 7.37–7.33 (m, 3H), 5.30 (s, 2H). 
Compound 114 
 
A solution of Pd2(dba)3•CHCl3 (35 mg, 0.033 mmol) and PPh3 (35 mg, 0.14 mmol) in 
THF (2 mL) was added to a solution of 113 (228 mg, 0.66 mmol), stannane 86 (350 mg, 
0.66 mmol), and CuI (25 mg, 0.14 mmol) in THF (5 mL). The mixture was heated at 
75°C for 12 h. The mixture was cooled to 0°C and diluted with EtOAc (10 mL). 
Saturated aqueous NaHCO3 (10 mL) was added and the mixture was stirred for 30 min. 
The layers were separated and the aqueous layer extracted twice with EtOAc (25 mL). 
The combined organic layers were washed with brine and dried over Na2SO4. The solvent 
was removed under vacuum and the resulting residue was subjected to flash silica gel 
column chromatography to provide the coupled product (30% EtOAc-hexane, Rf = 0.40) 
as a yellow solid (75%).(83) 1H NMR (CDCl3, 400 MHz) δ 7.84–7.74 (m, 2H), 7.64–7.61 
(m, 2H), 7.53–7.35 (m, 3H), 7.12 (bs, 1H), 7.00 (bs, 1H), 6.84 (s, 1H), 5.38 (s, 1H), 5.37–
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5.31 (m, 2H), 5.12–5.03 (m, 2H), 4.12–4.04 (m, 2H), 3.8–3.71 (m, 2H), 3.31 (s, 3H), 2.38 
(s, 3H), 2.05–1.95 (m, 1H), 1.34–1.29 (m,1H); 13C NMR (CDCl3, 100 MHz): δ 184.6, 
183.8, 158.4, 154.5, 144.8, 140.6, 139.6, 137.5, 136.3, 135.0, 134.8, 128.8, 128.0, 126.8, 
120.6, 120.5, 120.5, 120.0, 115.6, 100.2, 94.6, 71.0, 67.4, 67.3, 56.2, 25.6, 21.9. 
A solution of concentrated HCl (4 mL) in 20 mL CH3CN at 0 °C was added to the above 
coupled product (100 mg, 0.2 mmol) in a 250 mL flask. The mixture was stirred for 4 
min, quenched with NaHCO3 (75 mL), and EtOAc (50 mL) added. After separation of 
the layers, the aqueous layer was extracted with EtOAc twice. The combined organic 
layer was washed with brine, dried over Na2SO4. The solvent was then removed under 
vacuum and the resulting residue was subjected to purification by flash silica gel column 
chromatography (30% EtOAc-hexane, Rf = 0.25) to provide the desired product 114 as a 
yellow solid (70%).(83) 1H NMR (DMSO, 500 MHz) δ 9.97 (s, 1H), 9.83 (s, 1H), 7.82 
(dd, J = 8.4, 7.8 Hz, 1 H), 7.68 (d, J = 8.0 Hz, 1H), 7.63–7.61 (m, 3H), 7.45 (dd, J = 7.8, 
7.8 Hz, 2H), 7.35-7.33 (m, 1H), 7.31 (s, 1H), 7.08 (s, 1H), 6.78 (s, 1H), 5.38 (s, 2H), 2.38 
(s, 3H). 
Compound 116 
 
A solution of Pd2(dba)3•CHCl3 (5.4 mg, 0.005 mmol) and PPh3 (5.5 mg, 0.021 mmol) in 
THF (1 mL) was added to a solution of 115 (50 mg, 0.21 mmol), stannane 86 (114 mg, 
0.21 mmol), and CuI (4.0 mg, 0.021 mmol) in THF (4 mL). The mixture was heated at 75 
°C for 12 h. The mixture was then cooled to 0 °C and diluted with EtOAc (10 mL). 
Saturated aqueous NaHCO3 (10 mL) was added and the mixture was stirred for 30 min. 
The layers were separated and the aqueous layer was extracted twice with EtOAc (25 
mL). The combined organic layers were washed with brine and dried over Na2SO4. The 
solvent was removed under vacuum and the resulting residue was subjected to flash silica 
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gel column chromatography to provide the coupled product (20% EtOAc-hexane, Rf = 
0.20) as a yellow solid (75%). 1H NMR (acetone-d6, 500 MHz) δ 8.12-8.09 (m, 2H), 
7.89-7.87 (m, 2H), 7.16 (dd, J = 1.5, 1.0 Hz, 1H), 7.05 (dd, J = 1.5, 1.0 Hz, 1H), 6.91 (s, 
1H), 5.47 (s, 1H), 5.09 (d, J = 1 Hz, 2H), 4.02–3.95 (m, 2H), 3.84–3.72 (m, 2H), 3.31 (s, 
3H), 2.38 (s, 3H), 1.98–1.88 (m, 2H); 13C NMR (acetone-d6, 125 MHz) δ 185.3, 183.8, 
155.3, 148.3, 140.5, 139.1, 137.8, 134.8, 134.6, 133.4, 133.1, 127.3, 126.6, 121.2, 115.8, 
100.7, 95.2, 67.5, 56.2, 26.4, 21.8; HRMS (+EI): Calc’d for C23H22O6: 394.1416, 
observed: 394.1424. 
A solution of concentrated HCl (4 mL) in 20 mL CH3CN at 0 °C was added to the above 
coupled product (100 mg, 0.2 mmol) in a 250 mL flask. The mixture was stirred for 4 
min and then was quenched with NaHCO3 (75 mL) followed by addition of EtOAc (50 
mL). After separation of the layers, the aqueous layer was extracted with EtOAc twice. 
The combined organic layer was washed with brine, dried over Na2SO4 and the solvent 
was removed under vacuum. The resulting residue was subjected to purification by flash 
silica gel column chromatography (30% EtOAc-hexane, Rf = 0.20) to provide the desired 
product 116 as a yellow solid (65%). 1H NMR (acetone-d6, 500 MHz) δ 9.91 (s, 1H), 
8.90 (bs, 1H), 8.13-8.07 (m, 2H), 7.93-7.88 (m, 2H), 7.71-7.53 (m, 2H), 7.38 (s, 1H), .18 
(s, 1H), 6.97 (s, 1H), 2.45 (s, 3H); 13C NMR (acetone-d6, 100 MHz) δ 192.8, 185.2, 
184.4, 155.3, 147.5, 141.8, 137.8, 137.2, 134.8, 133.7, 133.3, 132.8, 129.6, 127.3, 126.6, 
126.0, 123.2, 21.6, HRMS (+EI): Calc’d for C18H12O4: 292.0735, observed: 292.0745. 
2-(3-(Methoxymethoxy)phenyl)-1,3-dioxane (118): This protected benzaldehyde was 
prepared in 2 steps. 
(a) 3-(1,3-dioxan-2-yl)phenol 
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A mixture of commercially available 3-hydroxybenzaldehyde (1.0 g, 8.19 mmol), 1,3-
propanediol (0.9 mL,1 2.29 mmol), and TsOH.H2O (60 mg, 0.3 mmol)  in toluene was 
refluxed with the azeotropic removal of H2O. After the starting material was consumed 
completely, the reaction mixture was cooled and the solvent was removed under pressure 
to give a residue. The crude residue was purified on silica (35% EtOAc-hexane, Rf = 
0.23) to give the protected aldehyde as a white solid in 79% yield. 1H NMR (CDCl3, 500 
MHz) δ 7.18 (t, J = 7.5 Hz, 1H), 7.016 (dd, J = 7.5, 0.5 Hz, 1H), 6.92 (dd, J = 2.0, 1.5 Hz, 
1H), 6.72 (ddd, J = 3.5, 2.5, 1.0 Hz, 1H), 6.22 (bs, OH), 5.45 (s, 1H), 4.27 (dd, J = 11.0, 
4.5 Hz, 2H), 4.0–3.95 (m, 2H), 2.25–2.20 (m, 1H), 1.45–1.42 (m, 1H); 13C (CDCl3, 125 
Hz) δ 155.9, 139.8, 129.7, 118.3, 116.3, 113.3, 101.6, 67.5, 25.7; HRMS (+EI): Calc’d 
for C10H12O3: 180.0786, observed: 180.0784. 
(b) 2-(3-(methoxymethoxy)phenyl)-1,3-dioxane (118) 
 
 Chloromethyl methyl ether (0.17 mL, 2.2 mmol) was added dropwise to a stirred 
solution of the above phenyl acetal (200 mg, 1.10 mmol) and diisopropylethylamine 
(0.29 mL, 1.76 mmol) in anhydrous CH2Cl2 and the mixture was heated at 40 °C. After 
24h, the reaction mixture was washed with H2O and brine. The combined organic layers 
were dried over Na2SO4 and the solvent was removed under vacuum to give MOM ether 
as colorless oil in 95% yield. 1H NMR (CDCl3, 500 MHz) δ 7.28 (t, J = 8.0 Hz, 1H), 
7.20-7.19 (m, 1H), 7.15-7.11 (m, 1H), 7.01 (ddd, J = 3.5, 2.5, 1.0 Hz, 1H), 5.44 (s, 1H), 
5.15 (s, 2H), 4.22–4.19 (m, 2H), 3.94–3.88 (m, 2H), 3.44 (s, 3H), 2.21–2.11 (m, 1H), 
1.38–1.33 (m, 1H); 13C NMR (CDCl3, 125 MHz) δ157.0, 140.2, 129.1, 119.4, 116.5, 
113.6, 101.1, 94.1, 67.1, 55.7, 25.5; HRMS (+EI): Calc’d for C12H16O4: 224.1048, 
observed: 224.1047. 
Compound 119 
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The above MOM ether (360 mg, 2.0 mmol) was co-evaporated twice with anhydrous 
toluene and was dissolved in freshly dried hexane (10 mL). At 0 °C, n-BuLi (0.96 mL, 
2.5M in hexane, 1.2 mmol) was added and the mixture was stirred for 30 min. A white 
precipitate indicated the formation of lithiated species. After 30 min, n-Bu3SnCl (0.9 mL, 
2.0 mmol) was added and the mixture was further stirred for 30 min, diluted with hexane-
Et2O (1:1, v/v), and saturated aqueous NaHCO3 added. The mixture was stirred at 0 °C 
for 30 min. After separation, the aqueous layer was extracted twice with hexane-Et2O 
(1:1, v/v). The combined organic layers were washed with brine and dried over Na2SO4. 
The solvent was removed under vacuum and the residue subjected to purification on 
silica to give the required stannane (4% EtOAc-hexane, Rf = 0.5) as colorless oil (88%). 
1H NMR (CDCl3, 500 MHz) δ 7.40 (d, J = 7.5 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.07 (d, J 
= 8.5 Hz, 1H), 5.40 (s, 1H), 5.12 (s, 2H), 4.24 (dd, J = 11.5, 4.5 Hz, 2H), 3.97 (t, J = 11.5 
Hz, 2H), 3.44 (s, 3H), 2.26–2.18 (m, 1H), 1.55–0.88 (m, 28H); 13C NMR (CDCl3, 125 
MHz) δ 161.8, 147.0, 130.1, 129.7, 119.9, 112.7, 102.3, 94.5, 67.2, 55.9, 29.2, 27.6, 25.8, 
13.8, 12.2; LRMS (+EI) [M-Bu]: 457. 
Compound 120 and 121 
 
A solution of Pd2(dba)3•CHCl3 (5.0 mg, 0.005 mmol) and PPh3 (5.0 mg, 0.019 mmol) in 
THF (1 mL) was added to a solution of 85 (48 mg, 0.19 mmol), stannane 119 (100 mg, 
0.19 mmol), and CuI (4.0 mg, 0.019 mmol) in THF (4 mL). The mixture was heated at 75 
°C for 12 h. The mixture was cooled to 0 °C and diluted with EtOAc (10 mL). Saturated 
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aqueous NaHCO3 (10 mL) was added and the mixture was stirred for 30 min. The layers 
were separated and the aqueous layer was extracted twice with EtOAc (25 mL). The 
combined organic layers were washed with brine and dried over Na2SO4. The solvent was 
removed under vacuum and the resulting residue was used in next step without further 
purification. 
A solution of concentrated HCl (2 mL) in 10 mL CH3CN at 0 °C was added to the above 
coupled product (30 mg, 0.07 mmol) in a 250 mL flask. The mixture was stirred for 4 
min, quenched with NaHCO3 (50 mL), and EtOAc (25 mL) added. After separation of 
the layers, the aqueous layer was extracted twice with EtOAc. The combined organic 
layers were washed with brine, dried over Na2SO4. The solvent was then removed under 
vacuum and the resulting residue subjected to purification by flash silica gel column 
chromatography to provide the desired product 120 along with partially protected MOM 
derivative 121.   
Compound 120: 1H NMR (acetone-d6, 400 MHz) δ 12.05 (bs, 1H), 9.96 (s, 1H), 9.08 
(bs, 1H), 7.81–7.77 (m, 1H), 7.62–7.57 (m, 3H), 7.37–7.34 (m, 2H), 7.02 (s, 1H); 13C 
NMR (acetone-d6, 100 MHz) δ 191.8, 190.2, 182.6, 161.2, 155.1, 148.0, 136.5, 136.4, 
131.7, 130.5, 128.6, 124.3, 123.6, 121.8, 120.4, 118.9, 115.3; HRMS (+EI): Calc’d for 
C17H10O5: 294.0528, observed: 294.0518. 
Compound 121: 1H NMR (acetone-d6, 500 MHz) δ 12.05 (bs, 1H), 10.03 (s, 1H), 7.83–
7.81 (dd, J = 8.5, 7.5 Hz, 1H), 7.73 (dd, J = 8.0, 6.0 Hz, 2H), 7.68–7.60 (m, 2H), 7.39 
(dd, J = 9.0, 1.0 Hz, 1H), 7.02 (s, 1H), 5.27–5.22 (m, 2H), 3.37 (s, 3H); 13C NMR 
(acetone-d6, 100 MHz) δ 192.6, 191.0, 183.5, 155.9, 148.8, 137.6, 137.6, 137.1, 133.5, 
131.6, 126.0, 125.0, 124.7, 121.3, 120.0, 116.2, 95.6, 56.5; HRMS (+EI): Calc’d for: 
C19H14O6:  338.0790, observed: 338.0791. 
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Summary  
A complete understanding of the biosynthetic machinery of the gilvocarcin 
pathway provides the foundation for our ultimate goal, to create gilvocarcin V analogues 
with improved pharmaceutical properties. In this context, it is imperative to understand 
the key C–C bond cleavage, intramolecular cyclization, and O-methylations that produce 
the unique structural scaffold. The isolation of the gilvocarcin gene cluster from S. 
griseoflavus in 2003 established the genetic basis for further biochemical studies. Now 
after a decade, GilOII has been unambiguously identified as the key enzyme performing 
the crucial C–C bond cleavage reaction and is responsible for the unique rearrangement 
of a benz[a]anthracene skeleton to the benzo[d]naphthopyranone backbone typical of the 
gilvocarcin-type natural anticancer antibiotics. Further investigation of this enzyme led to 
the isolation of a hydroxyoxepinone intermediate and thus several important conclusions 
regarding the cleavage mechanism. The FADH2-dependent oxygenase GilOII mediates 
C5–C6 bond cleavage via Baeyer-Villiger oxidation to give an acid-aldehyde 
intermediate which then undergoes decarboxylation to give the substrate for GilMT. The 
discovery has filled the puzzling decade old gap in the gilvocarcin biosynthetic pathway.  
GilMT and GilM, with previously unclear functions, were also investigated by in 
vitro studies using purified recombinant enzymes and synthetically prepared 
intermediates. The studies revealed GilMT as a typical S-adenosylmethionine dependent 
O-methyltransferase and GilM was identified as a pivotal enzyme in the pathway that 
exhibits dual functionality catalyzing the reduction of the quinone intermediate to a 
hydroquinone along with stabilizing O-methylation and a hemiacetal formation. GilM 
mediates its reductive catalysis by using the reduced flavin generated in GilR reaction. 
GilR catalyzes the final step in the gilvocarcin biosynthesis by converting pregilvocarcin 
to gilvocarcin. A 10-fold increase in the formation of defucogilvocarcin in the GilR-GilM 
reaction versus GilM alone confirmed the synergistic effects of GilR. However, to fully 
understand the complex interactions between GilM and FADH2, which is bicovalently 
tethered to GilR, we will need GilM structure. Other helpful information may be gained 
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from the structures of the corresponding enzymes ChryRM or RavRM, as both 
chrysomycin A and ravidomycin V contain the R- and the M-activity on the single gene. 
We extended our knowledge of post-PKS enzymes through our initial attempts of 
chemoenzymatic synthesis of defuco-pregilvocarcin M. In this perspective, we designed 
and synthesized a series of structural analogues of pathway intermediates. The in-vitro 
enzyme reactions with these analogues revealed that GilM and GilMT are both 
promiscuous enzymes. The two critical enzymes were shown to tolerate most of the 
substrates in the study. Following up on these preliminary studies, a more robust series of 
analogues must be designed and synthesized for a braoder structure-activity-relationship 
study. Particularly, analogues with more polar substituents like amino, sulfonic acid 
residues could serve as a solution to the difficult problem of developing water-soluble 
GV analogues. Small variations around the aromatic core could be very useful in 
increasing GV potency. Future studies involving characterization of GilGT, the 
glycosyltransferase involved in the pathway, are essential for the total chemoenzymatic 
synthesis of gilvocarcin type analogues. 
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